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ABSTRACT 
Type I interferons (IFNs) are known to cause neuropsychiatric side effects, including 
cognitive and mood disturbances, through mechanisms still not completely defined. 
To gain more information about type I IFN neurotoxicity, I investigated whether these 
cytokines could act directly on neuronal cells and regulate intracellular signaling 
pathways involved in cell death. In primary cultures of mouse cortical neurons acute 
exposure to IFN-β induces a marked tyrosine phosphorylation of signal transducer 
and activator of transcription (STAT) 1 and 3, whereas long-term exposure to the 
cytokine increased the number of neuronal cells displaying an increased labeling for 
cleaved caspase 3. In human SH-SY5Y neuroblastoma cells, used as a neuronal cell 
model,  type I IFNs rapidly stimulated the tyrosine phosphorylation of Janus kinase 
(JAK) and STAT1, STAT3 and STAT5 and this response was antagonized by 
blockade of type I IFN receptor. Prolonged exposure to IFN-β induced apoptotic cell 
death accompanied by cytochrome C release,  cleavage of caspase-9, -7, -3 and 
poly-(ADP ribose) polymerase (PARP), DNA fragmentation and p38 mitogen-
activated protein kinase (p38 MAPK) phosphorylation. JAK inhibition reduced IFN-β-
stimulated Tyk2 and STAT1 phosphorylation, STAT1 transcriptional activity, induction 
of double-stranded RNA-activated protein kinase (PKR), caspase cleavage and p38 
MAPK phosphorylation. PKR induction was associated with enhanced PKR activity 
and chemical inhibition of PKR reduced IFN-stimulated caspase activation. 
Moreover, long-term IFN-β treatment led to down-regulation of phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (Akt) signaling and IFN-β-induced apoptosis was 
attenuated in cells expressing constitutively active Akt. The proapoptotic effect of 
IFNs was markedly attenuated by pharmacological blockade of either glycogen 
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synthase kinase-3 (GSK-3) or p38 MAPK.  In retinoic acid-differentiated SH-SY5Y 
cells, treatment with IFN-β  inhibited BDNF-induced regulation of Akt and GSK-3β,  
activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2), 
phosphorylation of tyrosine hydroxylase, and neuritogenesis. Thus, type I IFNs can 
directly impair neuronal survival by regulating multiple mechanisms, including 
activation of the canonical JAK-STAT signaling and the ancillary p38 MAPK pathway 
and down-regulation of the PI3K/Akt and ERK1/2 signaling systems. The final 
outcome  of these molecular events is the activation of the apoptotic program and 
impaired neuronal differentiation in response to neurotrophic stimuli. It is proposed 
that these actions directed on neuronal cells may contribute to the neuropsychiatric 
disturbances elicited by these cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9
BACKGROUND 
Interferons (IFNs) are a family of structurally related cytokines with a hallmark 
function of antiviral activity. The characterization of the interferon genes, their 
expression, and their function was advanced with the development of novel 
techniques in molecular and cellular biology. The biomedical interest in IFN-α and 
IFN-β is linked to their therapeutic efficacy against viral infections, different types of 
cancer and neuroinflammatory diseases, particularly multiple sclerosis. However, 
these cytokines induce a number of peripheral and central adverse effects, which 
compromise tolerability and often limit the use of high dosage required to control 
cancer or viral disease. Among the most serious central side effects there are 
anxiety, confusion, mania, psychosis, cognitive deficits, depression and suicidal 
behaviour, through mechanisms still not completely defined. Depression has been 
reported to occur in 7–35% of patients depending on the duration of IFN treatment. 
Although the neuropsychiatric effects most often subside after IFN dosage reduction 
or discontinuation, there are reports that IFN neurotoxicity may persist for months or 
years after IFN withdrawal. The mechanisms that mediate the IFN neurotoxic effects 
remain unclear. Several physiological mechanisms have been proposed for the 
neurotoxic effects of IFNs, including actions mediated through neuroendocrine, 
neurotransmitter and cytokine pathways. 
It has been suggested that glia-derived factors may play a role in the alterations of 
monoamine neurotransmission and induction of neuropsychiatric side effects. 
However, an additional possibility is that type I IFNs may exert toxic effects directly 
on neuronal cells. Gene chip analysis of RNA from primary brain cell culture treated 
with IFN-α indicated that neurons are very responsive target cells for IFNs. At the 
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present, little is known on the expression of functional type I IFN receptors in human 
neuronal cells and on the ability of these cytokines to affect neuronal cell viability by 
regulating signaling pathways governing cell survival and apoptosis.  
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1. INTRODUCTION 
1.1 The interferon proteins 
The discovery of interferons (IFNs) dates almost 50 years ago when Alick Isaacs and 
Jean Lindenmann described for the first time the phenomenon of the viral 
interference (Isaac and Lindenmann, 1957). Their discovery stemmed from 
experiments in which the exposition of chicken  embryo cells to a strain of heat-
inactivated influenza virus A  stimulated cells to produce a secreted factor, which, 
when added to fresh cells, interfered with the replication of an active preparation of 
that same virus. This experiment led to the  discovery of the active component of the 
most common type of viral interference which was termed interferon.  Released IFNs 
were shown to act on specific receptors expressed on the cell membranes to induce 
the synthesis of proteins which block virus reproduction and diffusion in the 
organism. These observations led to test IFNs as potential therapy for infections by 
RNA and DNA viruses. Moreover, different studies demonstrated that IFNs not only 
regulate resistance to viral infections but also exert antiproliferative and 
immunomodulatory effects, suggesting their validity in cancer and autoimmune 
diseases (for a recent review, see Borden et al., 2007).  
In humans, seven IFNs species (termed α, β, Є, κ, ω, ν, and γ ) are found (Pestka et 
al., 2004) (Table 1) and are grouped into three classes called type I, II and III IFNs. 
The IFNs-α, -β, -Є, -κ, -ω, -ν are classified as Type I, whereas IFN-γ is the only Type 
II IFN. Type III IFNs comprises IFN-like proteins, such as interleukin (IL)-28A, IL-28B 
and IL-29 and can be induced in many cells. Unlike IFN-α and -β, the type III IFN 
receptor shows a limited tissue distribution (Meager et al., 2005; Mennechet & Uze, 
2006; Zhou et al., 2007).  These three  classes are defined by their differences in 
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amino acid sequences, physicochemical properties, induction by different agents 
(such as viruses, bacteria, bacterial products, polymers, low molecular weight 
compounds and antigens or mitogens) and cell source.  
 
Table 1 
 
Human IFN and IFN-like proteins 
from: Takaoka and Yanai, 2006 
 
 
Each IFN, with the exception of IFN-α, is a product of a single gene and thus present 
as a single protein or, in some cases, as few proteins differing by only few amino acid 
residues and considered allelic variants.  
So far, most of the studies focused on  IFN-α, IFN-β and IFN-γ. In humans, there are 
at least 12 different subtypes of IFN-α (besides one or two allelic variants for each 
subtype) that are encoded by 13 distinct genes (Table 2). These subtypes display 
high sequence homology (80%), whereas the identity with the other type I IFN is less, 
ranging from 60 to 30%. 
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Type I IFNs, including all IFN-α subtypes and IFN-β, are encoded by intron-less 
genes and are characterized by a secondary structure, comprising 5 α helices and 2 
disulfide bridges between Cys1/99 and 29/139, and a tridimensional conformation 
where the α helices are collected in a bundle. Type I IFNs  share similar biological 
activities as well as biophysical properties, such as retention of biological activity at 
low pH, which is not showed by IFN-γ. Accordingly, the sequence homology with 
IFN-γ is only 10%.  
The existence of a number of different type I IFNs acting on the same receptor raises 
the question of why this multigenic family has been conserved during evolution. 
Although the answer has not yet been reached, IFNs show important quantitative 
differences in their biological activities, suggesting distinct roles in innate immunity. A 
possible explanation for this diversity is that the mode of interaction of each IFN with 
the receptor might be different, possibly triggering intracellular signals that differ 
quantitatively and qualitatively among cell types and even in the same cell. 
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Gene Protein 
IFNA1 
IFNA2 
IFNA4 
IFNA5 
IFNA6 
IFNA7 
IFNA8 
IFNA10 
IFNA13 
IFNA14 
IFNA16 
IFNA17 
IFNA21 
IFNAP22* 
IFN-αD, IFN-α1 
IFN-α2a, IFN-α2b, IFN-α2c 
IFN-α4a, IFN-α4b 
IFN-αG, IFN-α5, IFN-α61 
IFN-αK, IFN-α6, IFN-α54 
IFN-αJ, IFN-αJ1, IFN-α7 
IFN-αB2, IFN-αB, IFN-α8 
IFN-αC, ΨIFN-α10, ΨIFN-αL, IFN-α6L 
IFN-α13 (sequence identical to IFN-α1) 
IFN-αH, IFN-αH1, IFN-α14 
IFN-αWA, IFN-α16, IFN-αO 
IFN-αI, IFN-α17, IFN-α88 
IFN-αF, IFN-α21 
YIFN-aE 
 
                                                                              Table 2 
Human IFNα genes (13) and proteins (12) 
* pseudogene 
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1.2 The IFNAR receptor 
The conservation of the multitude of type I IFNs, throughout evolution of the 
mammals is consistent with the unique functional roles for each of the type I IFN 
(Borden et al., 2007). IFN-α and IFN-β exert their biological actions by binding to and 
activating a common cell-surface heterodimeric receptor, named  IFN-α receptor 
(IFNAR), that consists of IFNAR1 and IFNAR2 chains.  
IFNAR1 is a glycoprotein consisting of an extracellular portion, containing four 
globular domains with two-layer β-structural conformation, a 21 amino acid 
transmembrane segment and a  100 amino  acid  cytoplasmic  domain (Origani et al.,  
2001). 
The IFNAR2 chain shows three different forms, the short form (IFNAR-2a), the 
soluble form (IFNAR-2b) and the long form (IFNAR-2c). The long form is  composed 
of 515 amino acids and works as a functional receptor for IFN-α and IFN-β. 
Early studies on type I IFN binding prior to the cloning of the receptor chains have 
indicated that most cell types display large variation in the number of binding sites 
(200–10,000/cell) and binding affinities. In particular, Scatchard analyses of binding 
isotherms identified two binding sites, one with a low (μM) and the other with a high 
affinity (nM–pM). This type of binding suggested the existence of a multicomponent 
receptor structure formed by a high affinity binding chain (termed the α chain) and a β 
or signal-transducing chain, that had a low binding affinity. The β chain, however, 
increased the affinity of  IFNs for the α chain from moderate (nM) to high affinity (pM). 
More recent investigations using recombinant IFNAR extracellular domains tethered 
to lipid membranes have shown that various type I IFNs bind to IFNAR2 with affinities 
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predominantly in the nM range (from 0.1 to 1000 nM), whereas they bind to IFNAR1 
with affinities mostly in the μM range (from 0.05 to 10 μM). 
How various type I IFNs can display different biological activities by acting on a 
common receptor is a still unresolved issue.  
It has been found that type I IFNs interact with the receptor differently and this 
property  may explain, at least in part, their different biological activities. A number of 
studies have investigated the residues of IFNAR2 involved in ligand interactions with 
IFN-α2 and  IFN-β. The ligand binding site of human IFNAR2 is composed largely of 
aliphatic hydrophobic amino acids. Three highly conserved residues Thr44, Met46, and 
Lys48 form the core of the IFNAR2 ligand binding domain, whereas residues, His76, 
Glu77, Tyr81, Trp100, Ile103, and Asp106 also facilitate IFN-α2 binding. These residues 
are predicted by NMR to form an extensive and largely aliphatic hydrophobic patch 
on the surface of IFNAR2. The interaction of IFN-β is predicted to be different from 
that of IFN-α,  which involves IFNAR2 residues Ile45 and Trp100, with minor 
contributions from Thr44, Met46, Ser47, and Ile103 (Fig. 1). The sequence differences 
between type I IFNs result in distinct binding affinities with each IFNAR chain with 
consequent possible differences in biological activities. Thus, analysis of IFNs 
binding to IFNAR extracellular domains tethered on solid-supported membranes 
indicated a critical role of the absolute affinity values toward IFNAR1 for 
antiproliferative activity (Jaks et al., 2007). An IFN-α2 mutant optimized for IFNAR1 
binding was also found to display enhanced antitumor activity (Kalie et al., 2007). 
Other studies using a panel of mutations targeting the IFN-α2 binding site to IFNAR2 
have confirmed the key role of IFNAR1 for the cytostatic effects, and have proposed 
that the differential biological activity of type I IFNs may result from the stability of the 
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IFN-IFNAR ternary complex, rather than the affinity of a given IFN for the individual 
receptor chains (Kalie et al., 2008).  
 
 
 
Fig. 1 
 
The type I IFN receptor ternary complex. Amino acid residues of IFN-α2  involved in IFNAR1 
interactions are shown in green  and those involved in IFNAR2 interactions are shown in violet. 
from: de Weerd et al., 2007 
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1.3 The JAK-STAT signaling pathway 
The binding of type I IFNs to the heterodimeric receptor  induces oligomerization. The 
cytoplasmic tail of IFNAR1 and IFNAR2 is pre-associated with tyrosine kinase 2 
(Tyk2) and JAK1, respectively, which belong to the Janus family of tyrosine kinases 
(JAK). Under basal conditions, the transcription factor STAT (Signal Transducers and 
Activators of Transcription) 2 is bound to the IFNAR2 chain and is weakly associated 
with STAT1 (Stancato et al., 1996; Precious et al., 2005a). IFN binding to the 
receptor induces the dimerization and a conformational change, such that Tyk2 
phosphorylates tyrosine 466 on IFNAR1, creating a strong docking site for STAT2. 
Tyk2 then phosphorylates STAT2 on tyrosine 690, and STAT1 is phosphorylated by 
JAK1 on tyrosine 701; the phosphorylated STAT1 and STAT2 can thus form a stable 
heterodimer. Phosphorylation of STAT1, its subsequent dimerization with STAT2 and 
the simultaneous phosphorylation of STAT2 inactivate the dominant constitutive 
nuclear export of STAT2 (Frahm et al., 2006), so that the dimers become transported 
into and retained in the nucleus until their dephosphorylation (reviewed by Reich and 
Liu, 2006). The STAT1–STAT2 complex associates with a p48 protein identified as 
IFN response factor 9 (IRF9), forming the  interferon-stimulated gene factor 3 
(ISGF3). 
The complex ISGF3 translocates to the nucleus and  initiates the transcription at IFN-
stimulated response elements (ISRE), thus activating interferon-stimulated genes 
(ISG) (Fig. 2).  
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Fig. 2 
Cellular signaling cascades triggered by IFNs 
from: Takaoka and Yanai, 2006 
 
The signaling pathways activated by type II and type III IFNs follow a very similar 
pattern to that developed in response to type I IFN (Zhou et al., 2007). The IFN-γ 
receptor is also a heterodimeric glycoprotein, composed by two types of major 
subunits, IFNGR1 and IFNGR2, that are weakly pre-associated in unstimulated cells. 
The cytoplasmic domains of the IFNGR1 and IFNGR2 receptor subunits are 
associated with a different set of JAKs, JAK1 and JAK2, respectively. The binding of 
IFN-γ to the receptor subunits initiates the signaling cascade by triggering receptor 
dimerization, which brings JAK1 and JAK2 into close proximity. This  results in the 
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activation of JAK2 which phosphorylates JAK1, thereby activating it. The activated 
JAKs phosphorylate a tyrosine-containing region in the C terminus of IFNGR1 
(between tyrosine 440 and tyrosine 444), creating a pair of binding sites for STAT1. 
Two STAT1 molecules interact via their SH2 domains with IFNGR1 and are 
phosphorylated at tyrosine 701, resulting in their activation and dissociation from the 
receptor. The activated STAT1 molecules dimerize through SH2 domain–tyrosine 
phosphate recognition, forming a STAT1 homodimer. This homodimer translocates to 
the nucleus, binds to the gamma-activation sequence (GAS) and stimulates 
transcription of ISGs. Importantly, this sequence is distinct from the ISRE, and the 
binding of the STAT1 homodimer does not require IRF-9.  
 
1.4 Negative regulation of JAK-STAT signaling  
IFNs also regulate different regulatory molecules to inhibit JAK-STAT pathway, thus 
limiting the extent of signaling. The suppressor of cytokine signaling (SOCS) 
proteins, the PIAS (protein inhibitors of activated STATs) proteins and different 
tyrosine phosphatases can inhibit JAK-STAT signaling through distinct mechanisms 
(Fig. 3).  
SOCS proteins are induced transcriptionally in response to cytokine stimulation, 
thereby providing a negative feedback circuit for IFN signaling modulation (Levy and 
Darnell, 2002; Rakesh and Agrawal, 2005). Although eight SOCS protein family 
members are known (SOCS1-7 and cytokine-inducible SH2 domain containing 
protein), the best characterized are SOCS1, SOCS2 and SOCS3. Each protein has a 
central SH2 domain,  an amino-terminal domain  of   variable  length, and a  carboxy- 
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Fig. 3 
Negative regulators of Jak/STAT signalling 
from: Rakesh and Agrawal,  2005 
 
 
terminal domain of 40-amino acid, known as the SOCS box. It has been proposed 
that SOCS proteins inhibit IFN signaling by binding to phosphorylated tyrosine 
residues on signaling intermediates, including receptor chains and JAKs, through 
their SH2 domain. SOCS family proteins, as well as other SOCS-box-containing 
molecules, probably function as E3 ubiquitin ligases and mediate the degradation of 
proteins associated through their amino-terminal regions. The SOCS box is also 
known to be important for stabilization and/or degradation of the SOCS1 and SOCS3 
proteins and mice that lack only the SOCS box of SOCS1 exhibited inflammatory 
diseases similar to complete SOCS1-deficient mice (Zhang et al., 2001). The role of 
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the SOCS box in the function of each of the SOCS proteins has not been full 
elucidated. 
PIAS are a group of constitutively expressed nuclear proteins that contain a zinc-
binding cysteine-rich RING finger domain, an  amino-terminal LXXLL co-regulator 
motif, a carboxy-terminal domain mediating TIF2 binding and a PINIT motif 
determining nuclear  retention (Wong et al., 2004). Five members of this family have 
been identified: PIAS1, PIAS3 α and β, PIASx and PIASy. PIAS proteins possess E3-
SUMO (small ubiquitin-related modifier) ligase activity promoting SUMO attachment 
to signaling proteins. Like protein ubiquitination, PIAS induced protein SUMOylation 
directs the substrates toward proteolytic degradation. PIAS proteins display some 
specificity for protein substrates, although not as high as that of ubiquitin ligases. 
PIAS1 and PIAS3 bind to STAT1 and STAT3, respectively, thereby preventing the 
interaction with DNA, whereas  PIASx forms a complex with STAT4 (You et al., 
1999). Besides inhibiting STATs, PIAS proteins can attack and repress other 
transcription factors, such as p53, c-Jun, androgen receptor, c-Myb and lymphoid 
enhancer factor 1 (LEF-1). 
Several cytoplasmic tyrosine phosphatases, including SHP-1, SHP-2, CD45 and 
PTP1B, participate in the negative control of JAK-STAT pathway by 
dephosphorylating tyrosine residues of receptor chains, JAKs and other signaling 
intermediates. SHP-1 and SHP-2 bind with their SH2 domains to phosphotyrosine 
residues of  different cytokine receptors.  
Studies have demonstrated that the carboxy-terminus of IFNAR1 contains a 
conserved region of about 14 amino acids, which inhibits type I IFN signaling. This 
region also contains residues required for the recruitment of E3 ubiquitin ligases, 
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ubiquitination and degradation of the receptor (Kumar  et al., 2004). Studies in knock-
out mice with null mutation in IFNAR1 have demonstrated that this component is 
essential for α and β IFNs-induced survival against most viral infections, 
myelopoiesis, B and T cell-mediated immune responses and  potent pro-
inflammatory response.   
               
1.5 Regulation of IFN expression 
Type I IFNs are produced by different cell types, such as dendritic cells, 
macrophages, monocytes and fibroblasts, whereas IFN-γ is exclusively produced by 
T lymphocytes. IFNs are inducible proteins and their constitutive production is very 
low in unstimulated cells. Exposure to a number of potentially noxious factors, such 
as viruses, bacteria, or their products (i.e. DNA fragments, single- or double-stranded 
(ds) RNA, bacterial toxins and lipopolysaccarides (LPS)), triggers IFN synthesis. 
Recently, the identification of toll-like receptors (TLR) greatly advanced the 
understanding of the mechanisms of IFN induction. TLR are a family of 
transmembrane receptors present either on plasma membranes, with the recognition 
domain located extracellularly and the signal transduction domain facing the 
cytoplasm, or on endosomal membranes. In the latter case,  the recognition domain 
is located inside the endosomes and the signal transduction domain oriented toward 
the cytoplasm in order to detect bacteria, viruses and their products following 
endosomal internalization (Fig. 4). In humans, at least 10 distinct TLR and 2 RNA 
helicases, retinoic acid inducible gene I (RIG-I) and melanoma differentiation 
associated protein 5 (MDA5), play a role as soluble cytoplasmic virus receptors. At 
least 5 distinct TLR (4 of which are expressed in endosomes) are involved in IFN 
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induction following viral infection. The initial observation that dsRNAs were potent 
inducers of IFNs suggested that viruses were capable of inducing IFNs by producing 
dsRNAs. 
          
Fig. 4 
 
Mammalian Toll-like receptors and their ligands 
from: Borden  et al., 2007 
 
It is now evident  that other virus gene products, besides dsRNA, can trigger IFN 
induction. Single-stranded (ss) RNAs can also be recognized, but only if they have 
5’-triphosphates. While ds- and ss-RNAs are recognized by TLR3, RIG-I and MDA5, 
an additional receptor is present in cytoplasm for viral DNA (Yoneyama and Fujita, 
2007). Other nucleic acids, such as ssRNAs, can act through TLR7 and TLR8, 
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whereas bacterial oligoDNAs act through TRL9. Bacteria LPS induces IFN by 
activating TLR4, whereas viral glycoproteins bind and activate different TLRs.  
The molecular mechanisms mediating IFN induction have been particularly studied  
for TLR3 and RNA helicases (Fig. 5). The inducers are recognized by TRL3, which 
undergoes tyrosine phosphorylation, dimerization and complex formation with CD14, 
thereby triggering a signal cascade leading to the recruitment of the TLR adapter 
molecule (TRIF). For RIG-1 and MDA5A a mitochondrial protein, termed IFN-β-
promoter stimulator 1 (IPS1), behaves as an adaptor. Both TRIF and IPS1 promote 
the recruitment of inhibitor of nuclear factor-κB (NFκB) kinase (IKK) and TANK-
binding kinase (TBK1/IKKE). TBK1 then phosphorylates and activates IFN regulatory 
factor (IRF) 3 and IRF7, which act as transcription factors. Activated IRFs dimerize 
and traslocate to the nucleus (Fig. 5).    
        
 
Fig. 5 
Signaling mechanisms by TLR3 and RNA helicases RIG-1/MDA5 
from: Borden  et al., 2007 
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It has been shown that IRF3 full  activation also requires phosphorylation by the 
protein kinase B/Akt, which is triggered by interaction of TLR3 with 
phosphatidylinositol 3-kinase (PI3K).  
The IKK protein kinase complex phosphorylates IkB and releases it from NFκB, 
which then can acts as transcription factor. Interestingly, signals originated by the 
adaptor protein IPS1 also lead to activation of caspases 10/8 through fas-activated  
death domain (FADD), thus suggesting that viral RNA can cause  both IFN induction 
and  cell death. 
In this complex molecular mechanisms of IFN induction,  several key steps can be 
altered leading to the development of virus resistance to IFN action. For example, it 
has been shown that a hepatitis C virus-encoded protease can cleave IPS1 off the 
mitochondria membrane and therefore block RIG-1 and MDA5 activity (Foy et al., 
2005). Proteins of hepatitis B virus, influenza virus, Ebola virus, papilloma virus and 
the human herpes Kaposi’s sarcoma-associated virus (KSHV) can also block IFN 
induction or the action of IFNs by different mechanisms (Garcia-Sastre and Biron, 
2006). For example, KSHV down-regulates one of the IFN-γ receptor chains, while 
the NS1 protein of influenza virus interacts with RIG-1.  
The knowledge of the basic molecular mechanism allowed the development of small-
molecule drugs that could induce IFN. CpG oligonucleotides, which are bacterial 
DNA oligodeoxynucleotide sequences including cytosine-guanosine, activate TLR9, 
whereas the quinolinamide imiquimod and its analogues stimulate TLR7 (Hemmi et 
al., 2000).  
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1.6 Mechanisms of IFN antiviral activity 
IFN-stimulated genes (ISGs) comprise more than 300 genes that mediate the 
biological and therapeutic effects of IFN stimulation. 
One of the biological actions of IFNs is the antiviral  activity, which involves  the 
production and the expression of more than 200 proteins in cells (Sadler and 
Williams, 2008). 
The role of all these proteins is unknown, although the expression of some of them is 
likely to be implicated directly in the antiviral action. In particular, the protein kinase R 
(PKR), the 2’-5’ oligoadenylate synthetase (2’-5’-OAS), and the protein Mx are the 
most characterized members of this class of proteins (Arnaud,  2002). 
 
1.6.1 The dsRNA-dependent protein kinase (PKR) 
The dsRNA-dependent protein kinase (PKR) is a critical mediator of the 
antiproliferative and antiviral effects of IFNs. PKR was identified following the 
observation that IFN-treated vaccinia virus (VV)-infected cells had a translational 
block of viral mRNAs and that cell extracts prepared from these cells showed 
restricted translation of viral and cellular mRNAs (Metz et al., 1972; Friedman et al ., 
1972). At that time, VV was known to produce dsRNA and dsRNA was also known to 
inhibit protein synthesis in animal cells or in cell free systems (Cordell-Stewart et al ., 
1973). It was demonstrated that extracts from IFN-pretreated cells had enhanced 
sensitivity to inhibition by dsRNA (Kerr et al., 1974). These studies identified a protein 
with dsRNA-dependent kinase activity, now known as PKR. 
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PKR is a serine-threonine kinase, composed by the kinase domain shared by the 
other kinases that phosphorylate the α subunit of eukaryotic initiation factor 2 (eIF-
2α) and two dsRNA binding domains that regulate its activity. PKR is one of the four 
mammalian kinases (the others are GCN2, PERK, and HRI) that phosphorylate eIF-
2α in response to stress signals, mainly as a result of viral infections (Barber, 2001; 
Dever, 2002; Harding et al., 2000; Williams, 1999). PKR autophosphorylation 
represents the activation reaction and leads to phosphorylation of eIF-2α at Ser51 . 
The phosphorylation prevents the recycling of eIF-2α that is required for ongoing 
translation, leading to general inhibition of translation.  
In addition to the kinase domain shared by the other eIF-2α kinases, PKR also has a 
dsRNA-binding domain that regulates its activity. As a consequence of dsRNA 
accumulation in infected cells, PKR-triggered eIF-2α phosphorylation also inhibits 
translation of viral mRNA (Balachandran et al., 2000; Lee et al.,1993; Stojdl et al., 
2000). This constitutes the basic mechanism by which PKR exerts its antiviral activity 
(Fig. 6). 
PKR activation regulates translational and transcriptional pathways (eIF-2a and NF-
kB-dependent) resulting in the specific expression of selected proteins (Fas, p53, 
Bax and others) that trigger cell death by engaging with the caspase pathway. 
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Fig. 6 
 The antiviral action of PKR 
 
1.6.2 The eukaryotic initiation factor-2 
In mammals, eIF-2 promotes Met-tRNAi delivery to the 40S ribosome to initiate 
polypeptide chain synthesis. eIF-2 is composed of three subunits (α, β and γ),  it 
binds the Met-tRNAi in a GTP-dependent manner to form the ternary complex, which 
joins the 40S subunit (Hershey, 1991). Once Met-tRNAi is delivered, eIF-2 is 
released from the initiation complex. Inactive eIF-2–GDP complexes are continuously 
regenerated by GDP-to-GTP exchange in a process catalyzed by the GTP exchange 
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factor eIF-2B. eIF-2 activity is regulated by phosphorylation at Ser51 of its α subunit. 
As a consequence of eIF-2α phosphorylation, eIF-2 affinity for eIF-2B increases up to 
100-fold, leading to competitive inhibition of eIF-2B and the resulting inhibition of 
translation initiation (Sudhakar et al., 2000) (Fig. 6). 
 
1.6.3  2′-5′-Oligoadenylate synthetase (2’-5’-OAS) 
The antiviral OAS/RNaseL system is an innate IFN-induced immunity pathway that 
responds to a pathogen-associated molecules to cause degradation of viral and 
cellular RNAs, thereby blocking viral infection (Fig. 7). 
The pathogen-associated molecule is dsRNA, a type of nonself-RNA produced 
during infections by both RNA and DNA viruses.  
Viral dsRNAs include replicative intermediates of ssRNA, viruses, viral dsRNA 
genomes, annealed viral RNAs of opposite polarities, and stem structures in 
otherwise viral ssRNAs. 
2’-5’-OAS, when activated by dsRNAs, polymerizes ATP into 2’-5’-linked oligomers of 
adenosine, referred to as 2’-5’ oligoadenylate (2’-5’-OA). The function of 2’-5’-OA is 
to activate a latent endoribonuclease L (RNaseL), responsible for degradation of viral 
and cellular RNAs. In humans four 2’-5’-OAS genes, named OAS1, OAS2, OAS3 
and OASL (OAS-like),  have been identified in the chromosome 12 (chromosome 5 in 
mice). OAS1 encodes two proteins of 40 and 46 kDa, that differ at their carboxy-
termini by 18 and 54 amino acids, respectively, have one catalytic domain and form 
tetramers. The OAS2 gene encodes two proteins of 69 and 71 kDa which have two 
catalytic domains and form dimers. The OAS3 protein has three catalytic domains 
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and is a monomer of 100 kDa. The OASL gene produces two proteins of 30 and 59 
kDa. 
The 2′-5-′OA-dependent RNaseL is expressed as a 80 kDa protein with two kinase-
like domains. The enzyme is constitutively expressed as an inactive monomer. 
Autoinhibition of the enzyme is relieved upon binding of 2′-5′-OA to the ankyrin 
repeats, and subsequent homodimerization. The active dimeric enzyme then 
degrades ssRNA . Due to their common action via RNaseL, the antiviral function of 
the OAS proteins has been investigated using RNaseL-deficient mice. These mice 
show increased susceptibility to RNA viruses from the Picornaviridae, Reoviridae, 
Togaviridae, Paramyxoviridae, Orthomyxoviridae, Flaviviridae and Retroviridae 
families. An antiviral role for RNaseL against DNA viruses is less directly established, 
although, as these viruses produce dsRNA replicative intermediates, they can induce 
2′-5′-oligomers.  
2’-5’-OAS activity is significantly induced at the acute stage of viral infections, likely 
as a consequence of virus-induced production of endogenous IFN-α (Read et al., 
1985; Schattner  et al., 1982;  Zachoval et al., 1990), and it usually returns to basal 
levels when infection resolves. 
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Fig. 7 
 
The OAS-RNaseL antiviral pathway 
from: Sadler and Williams,  2008 
 
 
1.6.4 The myxovirus (Mx) resistance proteins 
Other IFN-induced antiviral proteins are the Mx GTPases, MxA and MxB in humans 
and Mx1 and Mx2 in mice. The two human Mx proteins are encoded on chromosome 
21, in a region syngenic to the Mx region on mouse chromosome 16 (Aebi et al., 
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1989; Horisberger et al., 1988). The human proteins are cytoplasmic, as is the 
murine Mx2, whereas the murine Mx1 is nuclear. This differential distribution may 
allow each protein to target viruses that replicate in either cell compartment (Haller et 
al., 1995). Only human MxA has demonstrated antiviral activity, and this is directed 
against both nuclear and cytosolic viruses. 
The Mx proteins have a large (relative to many GTPases) amino-terminal GTPase 
domain, a central interacting domain (CID) and a carboxy-terminal leucine zipper 
(LZ). Both the CID and LZ domains are required to recognize target viral structures. 
The main viral target appears to be viral nucleocapsid-like structures (Kochs et al., 
1999). By virtue of their location at the smooth endoplasmic reticulum, Mx proteins 
can effectively control exocytotic events and modulate vesicle trafficking to trap 
essential viral components, thereby preventing viral replication at early time points   
(Accola et al.,  2002) (Fig. 8). 
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Fig. 8 
 
Mechanism of action of the antiviral protein MxA 
from: Sadler and Williams,  2008 
 
1.7 Clinical use of IFNs  
The biomedical interest in IFNs is linked to their therapeutic efficacy against viral 
infections (in particular against HCV and HBV), different types of cancer and 
neuroinflammatory diseases, particularly multiple sclerosis (Borden et al., 2007). 
Currently, IFNs are mainly employed as a standard therapy for hairy cell leukemia, 
metastasizing renal carcinoma and AIDS-associated angiogenic tumors of mixed 
cellularity known as Kaposi sarcomas. Three kinds of human IFNs (α, β, and γ), have 
been approved for clinical use by the Food and Drug Administration.  
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Table 3 
Clinical use of IFNs 
 
IFN-α species are most widely used for diseases of known viral origin, such as 
hepatitis C and hepatitis B. The very first treatment shown to be effective against 
HCV involved systematic administration of INF-α. Through the years, HCV treatment 
has improved with the development of modified pegylated-interferon (PEG-IFN), 
which has longer biological half-life. Currently, PEG-IFN and ribavirin combination is 
the standard treatment for HCV. Unfortunately, both these compounds are toxic and 
their administration causes a number of side effects. Moreover, the cost of therapy is 
very high and several months of therapy are required for eradication of chronic HCV 
infection, which is considered one of the major causes of chronic liver disease and 
one of the major causes  of death in the U.S.A. 
Protein Year Clinical use 
Interferon-α2a 1988 
Interferon-α2b 1986 
Melanoma; Kaposi sarcoma; 
non-Hodgkin lymphomas, leukemia;  
Chronic hepatitis B e C  
PEG-interferon-α2a 2002 
PEG-interferon-α2b 2001 
Chronic hepatitis C (± ribavirin) 
Interferon-α consensus 1997 Chronic hepatitis C 
Interferon-γ 1990 Osteopetrosis, granulomatosis 
Interferon-β1a 1996 
Interferon-β1b 1993 
Multiple sclerosis (relapsing/remitting
form) 
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IFN-β1b (Betaseron) and IFN-β1a (Avonex, Rebif), are approved for the treatment of 
relapsing-remitting multiple sclerosis (MS). MS is a chronic, potentially debilitating 
disease of unknown etiology  that affects the brain and the spinal cord. Treatment of 
MS with IFN-β was initiated based on the immunomodulatory properties of the IFNs. 
Well-controlled studies have shown that treatment with IFN-β results in a reduction of 
the annual rate of relapses of MS. Initiation of IFN-β treatment with the first instance 
of demyelination in MS appears to be a justified therapeutic intervention (Jacobs et 
al., 2000) 
With regard to IFN-γ, it is currently used in therapy for chronic granulomatous 
disease and skin lesions. 
 
1.8 Type I IFN side effects 
The therapeutic use of type I IFNs causes a number of peripheral and central 
adverse effects, which compromise tolerability and often limit the high dosage 
required to control cancer or viral disease (Vial et al., 2000; Raison et al., 2005).  
The number of different adverse events reported during therapy with IFNs is 
impressive (Fattovich et al., 1996). The identification of etiopathogenetic link with 
IFN-α administration may be difficult, especially if one considers that IFN-α must be 
administered continuously for several months: in the case of chronic hepatitis B for 
48-week, while in the case of chronic hepatitis C, the length of therapy may vary 
between 12 and 72 weeks, depending on the pattern of response. The most frequent 
effects reported by patients treated with IFNs are referred to as a typical flu-like 
syndrome with chills, fever, arthralgias, myalgias, rigours, headache, fatigue, 
weakness, and nonspecific digestive complaints like nausea, abdominal pain and 
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constipation. Altogether, flu-like symptoms are reported by almost all patients under 
therapy, are more intense after the first injections and tend to decrease after 4–6 
weeks from start. The reason why IFNs provoke fever is not clear. It has been 
postulated that IFNs may be directly pyrogenic in the hypothalamus, acting to 
increase prostaglandin production.  
The most important cause of drug withdrawal is the haematological toxicity, in 
particular neutropenia, due to the myelosuppressive effect. Moreover, 
myelosuppression-related anaemia is consistently observed after administration of 
IFNs. However, this effect is less worrying compared to the haemolytic anaemia 
caused by ribavirin, which is almost invariably administered concomitantly with IFN-α. 
IFNs treatment is also associated with the development of hypo- or hyperthyroidism 
(Fattovich et al., 1996). Up to 6% of treated subjects will develop thyroid 
abnormalities (Watanabe  et al., 1994; Deutsch  et al., 1997).  
 
1.9 Neurotoxicity of type I IFNs  
The most serious and dangerous IFN adverse effects involving  the  central nervous 
system are the neuropsychiatric disturbances. The spectrum of psychiatric side 
effects includes irritability, anxiety, depression, psychosis and suicide. Depression 
has been reported to occur in 7-35% of patients depending on the duration of IFN 
treatment (Vial et al., 2000; Raison et al., 2005). 
Although the neuropsychiatric effects most often subside after IFN dosage reduction 
or discontinuation, there are reports that IFN neurotoxicity may persist  for months or 
years after IFN withdrawal (Meyers et al., 1991).  
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Animal models have been used to study whether IFNs may have the potential to 
induce symptoms or changes associated with depression. Laboratory animal studies 
have been performed administering IFN peripherally or centrally in rodents. These 
studies have demonstrated  a dose-dependent increase in the immobility  time in the 
forced swimming test,  (Makino et al., 1998, 2000), an increase in corticotrophin 
releasing hormone (CRH) release in the amygdala and hypothalamus (Raber et al., 
1997), and a decrease in the brain dopamine and serotonin concentrations (Shuto et 
al., 1997; Kamata et al., 2000). In rhesus monkeys, 4 weeks of IFN therapy 
increased plasma concentration of adrenocorticotropic hormone and cortisol, and 
induced depressive-anxiety-like behaviors that resemble the human pathology 
(Felger et al., 2007). 
The pathogenesis of the neuropsychiatric side effects is still not completely 
understood. 
It has been suggested that IFNs may affect different neurochemical pathways 
putatively involved in the etiology of depression, including the serotonergic system, 
the hypothalamus-pituitary-adrenal (HPA) axis, the hypothalamus-pituitary-thyroid 
axis, and the cytokine network. 
IFNs are potent stimulators of the HPA axis, increasing the release of CRH and 
cortisol (Wichers and Maes, 2002; Felger et al., 2007), and evidence exists for a 
hyperactive HPA axis in depression (van West and Maes, 1999).  
Type I IFNs activate intracellular signaling pathways that may induce or inhibit the 
expression, or modify the effects of several cytokines, including IFN-γ, IL- 1, IL-2, IL-
6, IL-8, and TNF-α (Taylor and Grossberg, 1998).  
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Moreover IFNs can affect serotonin metabolism directly and/or indirectly by inducing 
the enzyme indoleamine 2,3-dioxygenase (IDO), which leads to a peripheral 
depletion of tryptophan and its conversion into kynurenine (Taylor and Feng, 1991). 
The kynurenine metabolites 3-hydroxy-kynurenine (3-OH-KYN) and quinolinic acid 
(QUIN) are neurotoxic, as demonstrated in animals and in vitro experiments (Okuda  
et al., 1998). Increased production of 3-OH-KYN and QUIN may also contribute to 
neuronal damage in cognitive decline of aging, infections of the central nervous 
system, ischemia, hypoxia at birth, traumatic injury and epilepsy. In addition, they 
may play a role in the development of psychiatric diseases such as anxiety, 
depression and schizophrenia (Stone et al., 2001; Reynolds  et al., 1988; Ogawa  et 
al., 1992) 
There is also evidence that peripherally administered IFNs can enter the brain and 
exert direct actions on brain structures (Pan et al., 1997; Thorne et al., 2008). In the 
brain, type I IFNs have been reported to cause alterations of opioid, monoamine and 
glutamate transmission and to induce cytokine and chemokine release from microglia 
(Kim et al., 2002; Dafny and Yang, 2005).  It has been suggested that glia-derived 
factors may play a role in the alterations of monoamine neurotransmission and 
induction of neuropsychiatric side effects (Raison et al., 2009).  
However, an additional possibility is that type I IFNs may exert toxic effects directly 
on neuronal cells. Gene chip analysis of RNA from primary brain cell culture treated 
with IFN-α indicated that neurons are very responsive target cells for IFNs (Wang 
and Campbell, 2005).  
At the present, little is known on the expression of functional type I IFN receptors in 
human neuronal cells and on the ability of these cytokines to  affect neuronal cell 
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viability by regulating signaling pathways governing cell survival and apoptosis (Fig.   
9).   
 
 
 
                                                            Fig. 9 
Possible cellular targets of type I IFNs in the Central Nervous System 
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2. RESEARCH SECTION 
2.1 Aims  
The aims of the study are: a) to investigate the expression and functional activity of 
IFN receptors in neuronal cells  and  their role in neuronal survival; b) to assess 
whether neurons represent a direct target of IFN neurotoxicity; c)  to identify 
pharmacological or genetic approaches capable of  preventing or counteracting the 
neuropsychiatric side effects elicited by these cytokines.  
 
The study  involved:  
a) the preparation of primary neuronal cell cultures and the assessment of their 
sensitivity to IFN action;  
b) the identification of a suitable neuronal cell line to study the direct neurotoxic 
action of IFNs;  
b) the analysis of the changes in cellular protein expression and phosphorylation 
induced by IFN treatment;  
c) the evaluation of the alterations in neuronal survival and synaptic plasticity 
following long-term incubation with IFNs. 
 
2.2 Materials and Methods 
2.2.1 Materials 
Recombinant human IFN-β1a, IFN-α2b and TNF-α, and mouse IFN-β were obtained 
from ProSpec-Tany TechnoGene Ltd (Rehovot, Israel). Recombinant human IFN-β1b 
and IFN-α2a were obtained from Schering (Milano, Italy) and Roche (Milano, Italy), 
respectively. Recombinant insulin–like growth factor I (IGF-I), all-trans-retinoic acid 
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(RA), phorbol 12-myristate 13-acetate (PMA)  AR A014418 and actinomycin D were 
from Sigma-Life Science (St. Louis, MO, USA). Pyridone 6 (P6),  PKR inhibitor and 
neutralizing mouse monoclonal anti-IFNAR2 antibody were from Calbiochem (San 
Diego, CA, USA). Normal mouse IgG was from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). The cell-permeable irreversible pan-caspase inhibitor Z-VAD-FMK 
was obtained from Biovision Research Products (Mountain View, CA, USA). 
Recombinant human brain-derived neurotrophic factor (BDNF) was obtained from 
Alomone Labs (Jerusalem, Israel). SB203580 and SB216763 were from Tocris 
(Bristol, UK) and Ascent Scientific (Bristol, UK), respectively. 
 
2.2.2 Preparation of primary cultures of mouse neuronal cells. 
 
Primary cultures of neurons derived from the cerebral cortex and subcortical 
structures (hippocampus and basal ganglia) were prepared from 1 day-old mice by 
using trypsin digestion as previously described (Olianas et al., 2008). Dissociated 
cells were collected by centrifugation and resuspended in Neurobasal A medium 
containing B27 serum-free supplement, 0.5 mM L-glutamine, 50 µM β-
mercaptoethanol and penicillin-streptomycin (Invitrogen). Cells were plated on either 
glass coverslips (Electron Microscopy Sciences, Fort Washington, PA, USA) or 12-
well plates pre-coated with 0.01% poly-L-lysine (Sigma) at a density of 1.5 x 104 and 
0.5 x 106 cells/cm2, respectively. The medium was removed 2 h later. Cultures were 
used five days after plating and contained 90 to 95% neuronal cells as assessed by 
immunofluorescence staining for neuron-specific enolase (NSE), neurofilament  
160/200 (NF160/200), which recognizes NF-M and NF-H (~ 160 and 200 kDa), and 
glial fibrillary acidic protein. Three separate culture preparations were used. 
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Experiments were performed according to the principles of laboratory animal care 
(Law on animal experiments in Italy, D.L. 116/92). 
 
2.2.3 Cell lines and culture conditions 
SH-SY5Y cells were obtained from the European Cell Culture Collection (Salisbury, 
UK) and grown in Ham's F12/MEM medium (1:1) supplemented with 2 mM L-
glutamine,1 % non-essential amino acids, 10% fetal calf serum (FCS) and 100 U/ml 
penicillin-100 µg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37°C in a 
humidified atmosphere containing 95% air and 5% CO2. Cells were used up to the 
16th  passage. Cells were differentiated by exposure to 10 µM RA for 6 days 
(Pahlman et al., 1984) or by sequential treatment with 10 µM RA for two days and 
100 nM PMA for two additional days (Pesgraves et al., 2004).  
HeLa cells (American Type Culture Collection, Manassas, VA, USA) were grown in 
Minimal Essential Medium (Invitrogen) supplemented with 10% FCS and L-glutamine 
at 37°C in a humidified atmosphere containing 95% air and 5% CO2. 
 
2.2.4 Cell treatment, immunoprecipitation and Western blot analysis 
Cells were washed with phosphate buffered saline (PBS) and incubated in medium 
containing 1% FCS. Cells were stimulated with IFNs as indicated at 37 °C in a 
humidified atmosphere of 5% CO2 in air. Inhibitors were dissolved in dimethyl 
sulfoxide (DMSO) and added before IFNs as indicated. The final concentration of 
DMSO in the incubation medium was < 0.5%. Control samples received an equal 
amount of vehicle. When the effect of mouse monoclonal anti-IFNAR2 antibody 
(Calbiochem) was examined, cells were pre-treated for 1 h with the indicated 
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antibody concentrations and then stimulated with IFN. Control samples were pre-
treated with equal concentrations of normal mouse IgG.  
Cells were washed and incubated with ice-cold cell lysis buffer containing PBS, 0.1 
% sodium dodecyl sulphate (SDS), 1 % Nonidet P-40, 0.5 % sodium deoxycholate, 2 
mM EDTA, 2 mM EGTA, 4 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 
10 mM sodium fluoride, 20 nM okadaic acid, 1 mM phenylmethylsulphonyl fluoride 
(PMSF), 0.1 % phosphatase inhibitor cocktail 1 and 1 % protease inhibitor cocktail 
(Sigma). The samples were sonicated for 5 s in ice-bath and aliquots of cell extracts 
were taken for protein determination by the method of Bradford (1976) using bovine 
serum albumin (BSA) as standard.  
For immunoprecipitation of insulin receptor substrate-1 (IRS-1), pre-cleared cell 
extracts were incubated with agarose-conjugated rabbit polyclonal anti-IRS-1 
antibody (Santa Cruz) overnight at 4 °C with continuous rocking. The beads were 
then washed four times with lysis buffer and mixed with electrophoresis sample 
buffer. 
Cell proteins were separated by SDS-polyacrylamide gel (SDS-PAGE) and 
electrophoretically transferred to nitrocellulose or polyvinylidene difluoride 
membranes (Amersham Biosciences, Piscataway, NJ, USA). The transfer efficiency 
was controlled by gel staining and by using pre-stained protein standards (Santa 
Cruz). Membranes were blocked by incubation in 20 mM Tris-HCl, 137 mM NaCl and 
0.1 % Tween-20 (pH 7.6) (TBS-T buffer) containing either 5 % BSA or 5 % non-fat 
dry milk (Santa Cruz) for 1 h. After washing with TBS-T buffer, the membranes were 
incubated overnight at 4 °C with one of the following primary antibodies: mouse 
monoclonal anti-phospho-(Tyr701)-STAT1, anti-phospho-(Tyr694)-STAT5 (detecting 
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both STAT5a and STAT5b), anti-pan STAT5a/b and anti-STAT3 (Zymed 
Laboratories, San Francisco, CA, USA); rabbit polyclonal anti-phospho-
(Tyr1054/1055)-Tyk2, anti-Tyk2, anti-procaspase-8, anti-cleaved caspase-9, anti-
procaspase-9, anti-cleaved caspase-7, anti-procaspase-7, anti-cleaved caspase-3, 
anti-procaspase-3, anti-cleaved poly-(ADP ribose) polymerase (PARP), anti-PARP, 
anti-PKR, anti-phospho-(Ser51)-eukaryotic initiation factor 2α (eIF2α), anti-eIF2α, 
anti-phospho-(Ser473)-Akt  and anti-phospho-(Ser9)-glycogen synthase kinase 
(GSK)-3β, anti phospho-(Thr180/Tyr182)-p38 MAP Kinase and rabbit polyclonal  
anti-ERK1/2  (Cell Signaling Technology, Danvers, MA, USA); rabbit polyclonal anti-
phospho-(Thr308)-Akt (GenWay Biotech. Inc., San Diego, CA, USA); rabbit anti-
phospho(Thr202/Tyr204)extracellular signal-regulated protein kinase 1 and 2 
(ERK1/2) (Neuromics, Northfield, MN); mouse monoclonal anti-phospho-(Tyr705)-
STAT3, anti-phospho-tyrosine (PY99), rabbit polyclonal anti-STAT1, anti-Akt1/2/3, 
anti-GSK-3β, and anti-IRS-1 (Santa Cruz); mouse anti-p38 MAPK (StressMarq 
Biosciences Inc.,  Victoria, Canada); mouse monoclonal anti-tyrosine hydroxylase 
(TH) and rabbit polyclonal anti-actin (Sigma);  rabbit polyclonal anti-phospho-(Ser31)-
TH (Chemicon-Millipore, Temecula, CA, USA), 
Thereafter, the membranes were washed and incubated with an appropriate 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz). 
Immunoreactive bands were detected by using ECL-Plus reagent and ECL Hyperfilm 
(Amersham). The size of immunoreactive bands was determined by using molecular 
weight standards detected with an ECL suitable antibody (Santa Cruz). Band 
densities were determined by densitometric analysis using Image Scanner III (GE 
Healthcare, Milan, Italy) and NIH ImageJ software (US National Institutes of Health, 
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Bethesda, MA, USA). The optical density of phosphoprotein bands was normalized to 
the density of the corresponding total protein or actin band to yield the relative optical 
density (ROD) value. 
 
2.2.5 Cell viability assay and morphological analysis 
Cells grown on glass coverslips (Electron Microscopy Sciences, Fort Washington, 
PA, USA) pre-coated with 0.01% poly-L-lysine (Sigma) were treated with either IFN-β 
(30 ng/ml) or vehicle for 24 h. Thereafter, cells were incubated with 1 µg/ml of 
propidium iodide (PI) (Sigma) for 1 h, washed, fixed in 4 % paraformaldehyde and 
incubated for with 0.1 µg/ml 4’,6-diamidino-2phenylindole dihydrochloride (DAPI) 
(Sigma). Coverslips were mounted with Gel Mount aqueous mounting medium 
(Sigma) and cells were examined by fluorescence microscopy by using an Olympus 
IX71 microscope. Images were captured over randomly selected fields using a 20 X 
objective lens and Olympus Fwiew II digital camera at constant settings and 
analyzed with the software Cell P (Olympus). PI positive cell nuclei were counted and 
their number expressed as percent of total nuclei. The number of fragmented and 
condensed nuclei was determined by DAPI staining. Three coverslips were used per 
experimental group and approximately 200 cells were counted in four random fields 
of each sample. For morphological examination, phase-contrast images were 
obtained from control and IFN-treated cells in randomly selected fields. Three 
separate preparations were analyzed by an investigator unaware of the experimental 
protocol. 
 
 
 47
2.2.6 Immunofluorescence analysis. 
For immunofluorescence analysis of phospho-STAT1, primary cultures of mouse 
neuronal cells or SH-SY5Y cells grown on pre-coated glass coverslips were treated 
for 30 min with either vehicle, mouse or human IFN-β.(30 ng/ml). For 
immunofluorescence analysis of cleaved caspase-3, cells were treated for 6 h with 
either vehicle or P6 (2 µM)  and then incubated for 24 h with either vehicle or mouse 
IFN-β (30 ng/ml).  
Cells were washed, fixed, permeabilized with 0.2 % Triton X-100 and blocked with 3 
% BSA and 1 % normal goat serum. Cells were then incubated overnight at 4 °C with 
either rabbit polyclonal anti-NSE (1:300) (Biomol, Hamburg, Germany) and mouse 
monoclonal anti-phospho-(Tyr701)-STAT1(1:200) or mouse monoclonal anti-
NF160/200 (1:500) (Sigma) and rabbit anti-cleaved caspase-3 (1:200). The cells 
were washed and incubated with a mixture of Alexa 488-conjugated goat anti-rabbit 
IgG (1: 3000) and Alexa 594-conjugated goat anti-mouse IgG (1:4000). After staining 
cell nuclei with DAPI, images were acquired over randomly selected fields using a 
40X objective lens and analyzed with Cell P software. Cells were deemed to be 
positive for cleaved caspase-3 if the average pixel intensity of the green fluorescence 
was equal or above a threshold value corresponding to one standard deviation above 
the average pixel intensity of the cells in control samples. The percent of positive 
cells was calculated as the number of positive cells / total number of nuclei stained 
by DAPI X 100. Three separate culture preparations were analyzed by an 
investigator unaware of the treatment. 
For neuritogenesis measurements, SH-SY5Y cells were differentiated in pre-coated 
glass coverslips in the presence of 10µM RA for 6 days. Thereafter, cells were grown 
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in a medium containing 1% FCS in the presence of the test agents for 48 h. 
Thereafter, cells were washed, fixed in 4 % paraformaldehyde, permeabilized with 
0.2 % Triton X-100 and blocked  for 1 h at room temperature with 3% BSA and 1% 
nonimmune serum appropriate for the secondary antibody. Cells were then incubated 
overnight at 4 °C with  anti-NF160/200 (1:500) followed by Alexa 594–conjugated 
goat anti-mouse IgG (1:4000).  After extensive washing, cells were incubated with 
fluorescein isothiocyanate (FITC)-labeled phalloidin (Sigma) for 1 h and the cell 
nuclei were stained with 0.1 µg/ml DAPI. Coverslips  were washed, covered with Gel 
Mount and  examined on an Olympus IX71 fluorescence microscope. The cell nuclei 
and neurites present in 12 randomly selected fields for each sample were counted. 
The ratio of neurites to cell nuclei was then determined for each experimental 
sample.  Assays were run in duplicates.  
 
2.2.7 RNA interference 
Human STAT1-p84/p91 small interfering RNA (siRNA) (sc-44123) and control siRNA 
were obtained from Santa Cruz. SH-SY5Y cells were transfected with siRNA 
oligonucleotides (50 pmol/ml) using Lipofectamine 2000 reagent (Invitrogen). 
 
2.2.8 Terminal transferase dUTP nick end-labeling assay (TUNEL assay) 
SH-SY5Y cells grown on glass coverslips were incubated with either vehicle (control) 
or IFN-β (30 ng/ml) for 24 h. The pan-caspase inhibitor Z-VAD-FMK was added at 
the concentration of 35 µM 3 h after IFN. When the effect of constitutively active Akt 
was examined, cells were transiently transfected with the construct myr-Akt1 
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(Millipore-Upstate, Temecula, CA, USA). Control cells were transfected with equal 
amount (0.2 µg) of empty vector. Cells were analyzed 48 h following transfection. 
Cells were fixed in ice-cold 4 % paraformaldehyde and permeabilized with 0.2 % 
Triton X-100. TUNEL assay was performed using the DeadEnd fluorimetric TUNEL 
system (Promega, Madison, WI, USA), according to the manufacturer’s instructions. 
Images were captured over randomly selected fields and analyzed with Cell P 
software. For each cell examined, the average pixel intensity of the green 
fluorescence in the nucleus was determined and corrected for the fluorescence 
intensity of an adjacent area, which was considered as background value. Cells were 
deemed to be positive if the average pixel intensity was equal or above a threshold 
value corresponding to one standard deviation above the average pixel intensity of 
the cells in control samples. The percent of positive cells was calculated as the 
number of positive cells / total number of nuclei stained by DAPI X 100. At least three 
separate culture preparations were analyzed by an investigator unaware of the 
treatment. 
 
2.2.9 Akt activity assay 
Akt activity was assayed by using a non-radioactive assay kit obtained from Cell 
Signaling Technology. Cells were treated with either vehicle or IFN-β (30 ng/ml) for 
24 h, washed with PBS and lysed in ice-cold cell lysis buffer containing 20 mM Tris 
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1µg/ml 
leupeptin and 1 mM PMSF. Samples were centrifuged and supernatants assayed for 
protein content. Aliquots containing equal amount of protein (0.8-1.0 mg) were added 
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to agarose crosslinked to mouse monoclonal anti-Akt antibody and incubated 
overnight at 4 °C with continuous rocking. The beads were then washed with cell 
lysis buffer and with kinase assay buffer containing 25 mM Tris (pH 7.5), 5 mM β-
glycerophosphate, 2 mM dithiothreitol,  0.1 mM sodium orthovanadate and 10 mM 
MgCl2. Thereafter, the beads were resuspended in kinase assay buffer 
supplemented with 0.2 mM ATP and 20 µg/ml  of GSK-3α/β crosstide (corresponding 
to residues surrounding Ser21/9 and expressed as GST-fusion protein) and the 
samples were incubated for 30 min at 30 °C. The reaction was stopped by the 
addition of sample buffer, the samples were heated at 100 °C and analyzed by 
Western blot using a rabbit polyclonal antibody against phospho-Ser21/9-GSK-3α/β. 
The blot was reprobed with an antibody against Akt to control enzyme 
immunoprecipitation and the optical density of the phospho-Ser21/9-GSK-3α/β band 
was normalized to the density of the corresponding Akt band. Three separate cell 
preparations were examined. 
 
2.2.10 Preparation of cellular fractions 
Cells were grown in 100 mm Petri dishes, incubated in medium supplemented with 1 
% FCS and treated for 24 h with either vehicle or 30 ng/ml IFN-β1b. Cells were 
harvested by scraping in ice-cold PBS, centrifuged at 600 g for 10 min at 4 °C and  
resuspended in ice-cold homogenization buffer (100 mM Tris/MOPS, 0.2 M sucrose, 
1 mM EGTA, pH 7.4, supplemented with 10 mM sodium fluoride, 1 mM PMSF, 0.1 % 
phosphatase inhibitor cocktail 1 and 1 % protease inhibitor cocktail). Cells were 
homogenized by using a Teflon/glass tissue grinder operated at 800 rpm (20 strokes) 
at ice-bath temperature, the homogenate was centrifuged at 1000 g for 10 min and 
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the supernatant centrifuged at 12,000 g for 15 min at 4 °C. To examine cytochrome C 
release, the supernatant was used as cytosolic fraction, whereas the pellet 
containing the mitochondria was washed and resuspended in 100 µl of 
homogenization buffer. Aliquots of each fraction containing an equal amount of 
protein were mixed with sample buffer and loaded on 12 % SDS-PAGE.   
 
2.2.11 Transfection-based reporter gene assay 
Cells were seeded in 12-well plates, incubated overnight and transfected with either 
400 ng/well of a reporter vector containing the interferon stimulated regulatory 
element (ISRE) located upstream of luciferase coding sequence (pISRE-Luc, 
Clontech Lab., Mountain View, CA, USA) or pTA-Luc vector as negative control by 
using the calcium phosphate transfection protocol according to the manufacturer’s 
instructions. Each sample was cotransfected with 2 µg of pSV-β-galactosidase 
control vector (Promega) as internal  control. After 12-14 h the medium was removed 
and the cells were treated with the test agents in 0.1 % FCS medium. Forthy hours 
post-transfection, cells were lysed with Reporter Lysis Buffer (Promega) and aliquots 
of the cell extracts were assayed for luciferase activity and for β-galactosidase 
activity by using the Bright-Glo Luciferase assay system and the β-Galactosidase 
enzyme assay system (Promega), respectively. The luciferase activity of each 
sample was normalized on the basis of the β-galactosidase activity. The experiments 
were carried out in triplicate. 
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2.2.12 Statistical analysis 
Results are reported as mean ± standard error of the mean (SEM). Data from 
concentration-response curves were analysed by the program Graph Pad Prism (San 
Diego, CA, USA.). Statistical analysis was performed by either Student’s t test or 
one-way ANOVA followed by Newman-Keuls post hoc test as appropriate. 
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3. RESULTS 
3.1 IFN-β induces STAT phosphorylation  and activates caspase-3 cleavage in 
primary neurons 
In primary cultures of mouse neuronal cells short-term treatment (30 min) with mouse 
IFN-β (30 ng/ml) elicited a marked increase of STAT1 and STAT3 tyrosine 
phosphorylation (Fig. 10a). Immunocytochemical analysis showed that IFN-β 
treatment increased phospho-Tyr-STAT1 labeling in cell bodies and processes of 
cells positive for the neuronal marker NSE (Fig. 10b).  
 
NSE pTyr-STAT1 overlay + DAPI
control
IFN-β
Fig. 10 
IFN-β induces STAT tyrosine phosphorylation and caspase-3 activation in primary neurons. (a) 
Cells were treated for 30 min with either vehicle or mouse IFN-β (30 ng/ml). Data are 
representative of three similar experiments. (b) Immunocytochemical analysis of STAT1 
tyrosine  phosphorylation in neuronal cultures treated for 30 min  with  either vehicle (control) or 
mouse IFN-β (30 ng/ml). Cells were stained for NSE (green) and phospho-Tyr-STAT1 (p-Tyr-
STAT1) (red). Nuclei were stained with DAPI. Images are representative of three separate 
experiments. Scale bar = 50 µm. Modified from: Dedoni et al., 2010 
(a) 
(b) 
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Long-term exposure (24 h) of primary neurons to mouse IFN-β (30 ng/ml) affected 
neuronal morphology, causing loss of neuritic processes and significantly increased 
the expression of cleaved caspase-3 (Fig. 11). 
 
 
Fig. 11 
 
Immunocytochemical analysis of  cleaved caspase-3 in neuronal cultures incubated for 24 h 
with either vehicle or mouse IFN-β (30 ng/ml). Neuronal cells were stained for NF160/200 (red) 
and cleaved caspase-3 (green). Nuclei were stained with DAPI. For each treatment the percent 
of cells positive for cleaved caspase-3 are reported. Values are the mean ± SEM of three 
experiments performed in three separate culture preparations. * p < 0.05 vs control (vehicle + 
vehicle). Scale bar = 50 µm. Modified from: Dedoni et al., 2010 
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2.3.2 IFN-α and IFN-β trigger JAK-STAT signaling  in SH-SY5Y cells. 
Although the primary cultures of mouse cortical cells contained 90-95% neurons, it 
might have been possible that the observed IFN effects on neurons  were mediated  
through the release  of other cytokines from the limited population of glial cells. To 
gain a more compelling evidence for a direct action of type I IFN on neuronal cells, 
the human neuroblastoma cell line SH-SY5Y, which constitutes a relatively 
homogeneous population of neuron-like cells, was employed. This cell line has been 
widely used as a cellular model to study the intracellular mechanisms mediating the 
actions of drugs on human neurons (Xie et al., 2010). 
As a first step, it was necessary to assess whether SH-SY5Y cells expressed 
functional type I IFN receptors. To this aim, the effects of a short-term exposure to 
IFN-α and IFN-β on Tyk2 and STAT tyrosine phosphorylation were investigated. As 
shown in Fig. 12 (a), IFN-α and IFN-β caused a rapid phosphorylation of Tyk2 on 
Tyr1054/1055 located in the kinase activation loop, an event required for enzyme 
activation. With both cytokines, Tyk2 phosphorylation reached a maximum at 
approximately 15 min and remained elevated for at least 30 min. Within the same 
time frame, IFN-α and IFN-β induced the phosphorylations of STAT1 on Tyr 701,  
STAT3 on Tyr705 and STAT5 on Tyr 694 (Fig. 12b-d), which are required for STAT 
dimerization and translocation to the nucleus (Levy and Darnell, 2002). Analysis of 
STAT1, STAT3 and STAT5 and their phosphorylated forms at longer IFN-β 
incubation times showed that STAT1 expression increased by two-fold (p < 0.001) at 
6 h and remained up-regulated at 24 h, whereas STAT3 was modestly enhanced 
only at 24 h (Fig. 12e). STAT5 expression was not significantly changed at each time 
point investigated (result not shown). Moreover, while phospho-STAT3 was detected 
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at 1 h but not at longer incubation times, phospho-STAT1 was still significantly 
enhanced at 3, 6, and 24 h of IFN-β exposure. Phosphorylation of STAT5 was not 
detected at 3, 6, and 24 h (results not shown). Thus, STAT1, STAT3 and STAT5 
displayed different long-term regulation by IFN-β.  
Type I IFN-induced tyrosine phosphorylation of Tyk2 and STATs occurred in a 
concentration-dependent manner and was saturable (Fig. 13a-d). IFN-α2a, IFN-α2b, 
IFN-β1a and IFN-β1b stimulated STAT1 phosphorylation with  EC50 values of 0.54 ± 
0.07, 1.70 ± 0.2, 1.50 ± 0.09 and 0.40 ± 0.06  ng/ml, respectively. Similar EC50 values 
of IFN-α2a and IFN-β1b were observed for the stimulation of STAT3 phosphorylation 
(1.69 ± 0.08 and 1.53 ± 0.07 ng/ml, respectively), STAT5 (0.70 ± 0.10 and 0.99 ± 
0.09 ng/ml, respectively) and Tyk2 phosphorylation (1.40 ± 0.06 and 1.60 ± 0.20 
ng/ml, respectively). The involvement of specific type I IFN receptor was investigated 
by using a neutralizing antibody directed against the IFNAR2 subunit of the receptor. 
As shown in Fig. 13 (e), pre-incubation of the cells with the anti-IFNAR2 antibody 
elicited a concentration-dependent inhibition of IFN-β-stimulated STAT1 tyrosine-
phosphorylation.  
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Fig. 12 
 
Type I IFNs induce Tyk2 and STAT 
phosphorylation in a time-
dependent manner. SH-SY5Y cells 
were treated with either 30 ng/ml of 
IFN-β1b or IFN-α2a for the 
indicated times. Zero-time samples 
were treated with vehicle. The 
phosphorylated and total forms of 
Tyk2 (a), STAT1 (b), STAT3 (c) 
and STAT5 (d) were measured in 
cell extracts by Western blot. ROD 
values are expressed as 
percentage of the maximal 
stimulation. Data are the mean ± 
SEM of  three-four experiments. 
(e) Regulation of STAT1 and 
STAT3 by long-term exposure to 
IFN-β. Cells were treated with 
either vehicle or IFN-β1b (30 
ng/ml) for the indicated times and 
the phosphorylated and total forms 
of  STAT1 and STAT3 were 
measured in cell extracts by 
Western blot. ROD values of 
STAT/actin and pSTAT/STAT are 
reported as percentage of the 
corresponding control values and 
as percentage of maximal 
stimulation, respectively. Data are 
the mean ± SEM of three 
experiments. * p < 0.05, ** p < 0.01 
vs the corresponding value at 1 h 
after IFN;  # p < 0.05, ## p < 0.01 
vs control at the same time point. 
from: Dedoni et al., 2010 
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Fig. 13 
 
Concentration-dependent stimulation 
of Tyk2 and STAT phosphorylation by 
type I IFNs and blockade by anti-
IFNAR2 antibody. Confluent SH-SY5Y 
cells were treated with either vehicle or 
the indicated concentrations of each 
IFN subtype for 15 min. The 
phosphorylated and total forms of 
STAT1(a), STAT3 (b), STAT5 (c) and 
Tyk2 (d) were measured by Western 
blot and the corresponding ROD 
values are reported as percentage of 
maximal stimulation. Data are the 
mean ± SEM of three experiments. (e) 
Antagonism of IFN-β-induced STAT1 
phosphorylation by anti-IFNAR2 
antibody. Cells were pre-treated for 1 h 
with the indicated concentrations of 
either anti-IFNAR2 antibody or normal 
mouse IgG and then incubated with 
either vehicle or 3 ng/ml IFN-β1b for 15 
min. The phosphorylated and total 
forms of STAT1 were measured and 
ROD values reported as percentage of 
the maximal stimulation. Data are the 
mean ± SEM of  three experiments. 
from: Dedoni et al., 2010 
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2.3.3 IFN-β induced neuronal cell death in SH-SY5Y cells 
To investigate the effect of type I IFN on human neuronal survival, SH-SY5Y cells 
were exposed for 24 h to either vehicle or IFN-β (30 ng/ml). Examination of the cells 
by light microscopy showed that the cytokine treatment altered cell morphology, 
causing process shortening and cell bodies rounding and shrinkage (Fig. 14a). 
Fluorescence microscopy analysis of PI and DAPI staining (Fig. 14b,c) indicated that, 
while vehicle treatment had no effect of cell viability, 24 h exposure to IFN-β induced 
the appearance of dead cells (control 2.0 ± 0.8, IFN-treated 24 ± 5 % of total nuclei 
stained by DAPI, p < 0.01), and an increase of the number of cells displaying 
fragmented and condensed nuclei (control 2.5 ± 0.7, IFN-treated  20 ± 3 % of total 
nuclei, p < 0.01), suggesting the occurrence of apoptosis. By using in situ TUNEL 
technique (Fig. 14c), it was observed that in IFN-β-treated samples a higher 
percentage of cell nuclei showed DNA fragmentation, a hallmark of apoptosis, and 
this effect was significantly reduced by the addition of the pan-caspase inhibitor Z-
VAD-FMK (35 µM), indicating that IFN-induced neuronal death was dependent on  
caspase activation. The percent values of TUNEL positive nuclei were: control  3.1 ± 
0.4, IFN-β 20 ± 1.6 (p < 0.01 vs control), Z-VAD-FMK 3.6 ± 0.4, IFN-β + Z-VAD-FMK 
12 ± 0.9 (p < 0.05 vs IFN-β). 
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Fig. 14 
 
IFN-β induces apoptosis in SH-
SY5Y cells. Cells were incubated 
for 24 h with either vehicle (control) 
or IFN-β1b (30 ng/ml) and then 
examined by light microscopy for 
morphological analysis (a) and by 
fluorescence microscopy for PI (b), 
DAPI (c) and DAPI plus TUNEL 
labeling (d). In (c) arrows and 
arrow heads indicate condensed 
and fragmented nuclei, 
respectively. In (d) cells were 
incubated with either vehicle 
(control), IFN-β, Z-VAD-FMK (35 
µM) and IFN-β + Z-VAD-FMK. 
TUNEL positive nuclei are stained 
with green or light blue. 
Micrographs are representative of 
3-4 experiments. In (a), scale bar = 
100 µm and applies to all 
micrographs. 
from: Dedoni et al., 2010 
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2.3.4 Effects of IFN on  HeLa cell viability. 
To explore whether IFNs were also capable of inducing cell death in non-neuronal 
cells, we examined the sensitivity of HeLa  cells to the long-term (24 h) treatment 
with 30 ng/ml IFN-β, which was observed to cause apoptosis in primary neurons and 
SH-SY5Y cells. As shown in Fig. 15, the IFN-treatment failed to alter the morphology 
and viability of HeLa cells. 
 
 
  
 
  
 
  
 
Fig. 15 
 
Long-term treatment with IFN-β fails to affect cell morphology and viability of Hela cells. Cells 
were incubated for 24 h with either vehicle (control) or IFN-β1b (30 ng/ml) and then examined 
by light microscopy for morphological analysis (upper panel) and by fluorescence microscopy 
for PI (red) and DAPI (blue) (lower panels). Scale bar = 100 µm  
Control IFN-β
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To assess whether HeLa cells cultured under the described conditions were sensitive 
to type I IFNs, the ability of the cytokines to induce STAT1 tyrosine phosphorylation 
was investigated. As reported in Fig. 16, IFN-β1b and IFN-α2b caused a robust  
increase in phospho-(Tyr701)-STAT1 with EC50 values of 109 ± 34 and 133 ± 35 
pg/ml (n = 3).             
 
 
 
 
 
 
 
2.3.5 IFN-β induced cytochrome C release and caspase activation  
In mammalian cells, apoptosis occurs through two major routes, the mitochondrial 
“intrinsic” apoptotic pathway and the “extrinsic” pathway (Hengartner, 2000). In the 
“intrinsic” pathway, the loss of outer mitochondrial membrane integrity causes the 
release of cytochrome C, which binds to and activate the apoptotic protease 
Fig. 16 
 
Concentration-dependent stimulation of STAT1 phosphorylation by type I IFNs in HeLa 
cells. Confluent cell cultures were treated with either vehicle or the indicated 
concentrations of each IFN subtype for 15 min.  Phospho-(Tyr701)- STAT1 and actin 
immunoreactivities were measured by Western blot and the corresponding ROD values 
are reported as percentage of maximal stimulation. Data are the mean ± SEM of three 
experiments. 
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activating factor-1, with subsequent activation of caspase-9 and executioner 
caspases-7, -6 and -3. In the extrinsic pathway, stimulation of cell-surface death 
receptors initiate apoptosis by activating caspase-8, which then triggers the activation 
of executioner caspases. To investigate the involvement of these apoptotic pathways 
in SH-SY5Y cells, the effects of IFN-β on mitochondrial cytochrome C release and 
caspase activation were examined. In vehicle-treated cells the presence of 
cytochrome C in the cytosol was almost undetectable, whereas in cells treated with 
IFN-β there was a marked increase in cytosolic cytochrome C concentration (Fig. 
17a). This change was associated with a robust activation of the caspase proteolytic 
cascade, as indicated by the increase of the cleaved forms of caspase-9 (37 kDa) 
(Fig. 17b), caspase-7 (20 kDa) (Fig. 17c) and caspase-3 (20 and 17 kDa) (Fig. 17d). 
Exposure to IFN-β also caused an increased expression of procaspase-7 (Fig. 17c), 
whereas the levels of procaspase-9 and procaspase-3 were either unaffected or 
decreased. On the other hand, no detectable expression of either full length caspase-
8, its cleaved intermediate p43/p41 or caspase 8 active fragment p18 was observed 
in cell extracts of control cells and cells treated for 24 h with either 30 ng/ml IFN-β, 
IFN-α or 25 ng/ml TNF-α (results not shown). These data indicate that IFN-β caused 
neuronal cell death through the mitochondrial “intrinsic” apoptotic pathway. The 
activation of the executioner caspases was assessed by examining the cleavage of 
PARP, a downstream target of activated caspase-3 and caspase-7. IFN-β treatment 
enhanced the formation of the 89 kDa cleaved form of PARP in a concentration-
dependent manner (Fig. 17e). The estimated EC50 value of IFN-β (0.86 ± 0.07 ng/ml) 
correlated with the cytokine potency in stimulating Tyk2 and STAT phosphorylation. 
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Fig. 17 
 
Induction of cytochrome C release 
and activation of caspase cascade 
by IFN-β. SH-SY5Y cells were 
treated with either vehicle (control)  
or IFN-β1b (30 ng/ml) for 24 h. (a) 
Cytochrome C and actin were 
measured in cytosol and 
mitochondrial fraction (mitoch) by 
Western blot. Cytosolic 
cytochrome C/actin ROD values 
are reported as percentage of 
control. Data are the mean ± SEM 
of  three experiments. *** p < 
0.001. (b-d) Cleaved fragments of 
caspase-9, -7 and -3 and their 
corresponding procaspase forms 
were measured and the ROD 
values are reported as fold of 
stimulation. Data are the mean ± 
SEM of  three experiments. *** p < 
0.001 vs control. (e) Cells were 
treated with either vehicle or the 
indicated concentrations of IFN-
β1b for 24 h and the cleaved and 
native forms of PARP were 
measured by Western blot. ROD 
values are expressed as percent of 
stimulation with respect to vehicle-
treated control.  Data are the mean 
± SEM of  three experiments. * p < 
0.05, *** p < 0.001. 
from: Dedoni et al., 2010 
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2.3.6 Blockade of JAK activity inhibits IFN-β-induced STAT signaling and 
caspase activation. 
Previous studies in non-neuronal cell types have shown that the JAK-STAT pathway 
plays a pivotal role in type I IFN regulation of gene expression and cell  growth, 
proliferation and survival (van Boxel-Dezaire et al., 2006). The possible involvement 
of this pathway in IFN-β-induced apoptosis in SH-SY5Y cells was studied by using 
P6, a pan JAK inhibitor (Thompson et al., 2002; Pedranzini et. al., 2006). Pre-
treatment of the cells for 6 h with P6 (2 µM) significantly attenuated IFN-β stimulation 
of Tyk2, STAT1 and STAT3 tyrosine phosphorylation (Fig. 18a-c). To assess whether 
P6-induced inhibition of JAK-STAT signaling translated into impaired STAT-
dependent gene transcription, cells were transiently transfected with a luciferase 
reporter gene containing the ISRE sequence, which is activated by STAT1-STAT2 
heterodimers associated with the DNA-binding subunit IRF-9 (de Weerd et al., 2007; 
Schindler et al., 2007), In vehicle-treated cells, IFN-β induced a 3-fold increase of 
ISRE transcriptional activity, which was markedly reduced by pre-treatment with P6 
(Fig. 18d). Moreover,  cell treatment with P6 significantly reduced the cleavage of 
caspase-9, -7, -3 and PARP triggered by exposure to IFN-β (Fig. 19a-d).  
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Fig. 18 
 
Blockade of IFN-β-stimulated JAK-STAT 
signaling by P6. SH-SY5Y cells were 
treated with either vehicle or P6 (2 µM) 
for 6 h and then exposed to either vehicle 
or IFN-β1b (30 ng/ml) for 15 min. (a-c) 
The phosphorylated and total forms of 
Tyk2, STAT1 and STAT3 were measured 
by Western blot and the corresponding 
ROD values are expressed as 
percentage of maximal stimulation. Data 
are the mean ± SEM of three 
experiments. (d) ISRE transcriptional 
activity in cells transfected with ISRE-
luciferase reporter plasmid, treated with 
either vehicle or P6 (2 µM) and then 
exposed to  either vehicle or IFN-β1b (30 
ng/ml) for 1 h. Data are the mean ± SEM 
of three separate experiments.  
*** p < 0.001 vs control. 
from: Dedoni et al., 2010 
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2.3.7 IFN-β enhances PKR expression and activity 
Among the multiple IFN-stimulated genes, PKR is one of the most involved in the 
regulation of cell growth, differentiation and apoptosis (Samuel et al., 1997). PKR 
mediates translational control in response to dsRNA and other cellular stress stimuli 
by phosphorylating the α subunit of the translation initiation factor eIF2 on Ser51. 
Once phosphorylated by PKR, eIF-2α enhances the affinity for GDP and thus inhibits 
translation initiation events. Prolonged IFN-β treatment of SH-SY5Y cells increased 
the expression of PKR, which was detected at 6 h and persisted for at least 24 h (Fig. 
20a). IFN-β-stimulated PKR induction was completely prevented by pre-treatment 
with either P6 (2 µM) (Fig. 20b) or the transcription inhibitor actinomycin D (100 ng/ml 
for 3 h) (results not shown). Moreover, cell transfection with STAT1 siRNA reduced 
Fig. 19 
 
Blockade of JAK-STAT signaling 
inhibits IFN-β-stimulated caspase 
activation. SH-SY5Y cells were 
treated with either vehicle or P6 (2 
µM) for 6 h and then exposed to 
either vehicle or IFN-β1b (30 
ng/ml) for 24 h. (a-d) Cleaved 
caspase-9, -7, -3 and PARP and 
the corresponding native forms 
were measured and the ROD 
values are reported as percentage 
of stimulation. Data are the mean ± 
SEM of three experiments. 
from: Dedoni et al., 2010 
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basal and IFN-β-stimulated STAT1 expression by 60 and 50%, respectively, and 
completely blocked the increase in PKR levels elicited by IFN-β (Fig. 21). IFN-β 
treatment also enhanced the phosphorylation of eIF-2α, indicating an increased PKR 
activity (Fig. 20c). To investigate the role of PKR in neuronal apoptosis elicited by 
IFN-β, a chemical inhibitor of PKR (Jammi et al., 2003; Shimazawa and Hara, 2006) 
was employed. Pre-treatment of SH-SY5Y cells with PKR inhibitor (1 µM) 
significantly reduced IFN-β-stimulated eIF-2α phosphorylation (Fig. 20c) and curtailed 
IFN-β-induced activation of caspase-7 and PARP proteolysis (Fig. 20d,e). 
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Fig. 20 
 
PKR is induced by IFN-β and 
promotes caspase activation. (a) 
Time-dependent enhancement of 
PKR expression by IFN-β. SH-
SY5Y cells were treated for the 
indicated times with either vehicle 
or IFN-β1b (30 ng/ml) and PRK 
and actin immunoreactivities were 
analyzed by Western blot.  ROD 
values of IFN-treated samples are 
reported as percentage of control 
values at each time point. Data are 
the mean ± SEM of three 
experiments; *** p < 0.001 vs the 
corresponding control value. (b) 
Blockade of PKR induction by P6. 
Cells were treated with either 
vehicle or P6 (2 µM) for 3 h and 
then exposed to either vehicle or 
IFN-β1b (30 ng/ml) for 6 h. ROD 
values are reported as percent of 
control and are the mean ± SEM of 
three experiments; * p < 0.05 vs 
control. (c) IFN-β enhances PKR 
activity. Cells were incubated for 1 
h with either vehicle (control) or 1 
µM PKR inhibitor (PKR inhib) and 
then with either vehicle or IFN-β1b 
(30 ng/ml) for 24 h. Cell extracts 
were analyzed by Western blot 
with antibodies to phospho-Ser51-
eIF2α and total eIF2α. ROD values 
are reported as percentage of 
control. Data are the mean ± SEM 
of three experiments. *** p < 0.001 
vs control. (d,e) Inhibition of PKR 
prevents IFN-β-induced caspase-7 
and PARP cleavage. Cells were 
incubated for 1 h with either 
vehicle (control) or 1 µM PKR 
inhibitor and then with either 
vehicle or IFN-β1b (30 ng/ml) for 
24 h. Cleaved caspase 7, 
procaspase-7, cleaved PARP and 
PARP were analyzed by Western 
blot. ROD values are reported as 
percentage of maximal effect. Data  
are the mean ± SEM of three 
experiments.  
from: Dedoni et al., 2010 
 
 70
 
 
 
2.3.8 Involvement of p38 MAPK in type I IFN-induced apoptosis 
Mitogen-activated protein kinases (MAPK) are a group of widely expressed serine-
threonine protein kinases that mediate cellular responses to different extracellular 
signals (Schaeffer and Weber, 1999). Three distinct families of MAPK have been 
identified: the extracellular-signal regulated kinases (ERK), the Jun N-terminal 
kinases (JNK) and the p38 MAPK. There are four p38 isoforms with high sequence 
homology and are designated p38α, p38β, p38γ and p38δ (Schaeffer and Weber, 
1999). It has been shown that, like JNK,  p38 MAPK are activated by different 
stressful stimuli, including UV irradiation, heat, osmotic shock, genotoxic agents, 
toxins, and cytokines (Kumar et al., 2003; Wagner e Nebreda, 2009). Previous 
 
Fig. 21 
 
Knockdown of STAT1 prevents 
PKR induction by IFN-β. Cells 
were transfected with either control 
siRNA or STAT1 specific siRNA 
and 48 h later incubated for 6 h 
with either vehicle or  the indicated 
concentrations of IFN-β. Cell 
extracts were then analyzed for 
STAT1 (a) and PKR (b) expression 
by Western blot. The results are 
the mean ± SEM of three 
experiments. *** p < 0.001 vs 
control (control siRNA + vehicle); # 
p < 0.05; ### p < 0.001 vs the 
corresponding value in control 
siRNA treated samples. 
from: Dedoni et al., 2010 
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studies have shown  that in non-neuronal cells type I  IFN can induce p38  MAPK 
activation through a signaling cascade possibly involving JAK, the guanine exchange 
factor Vav, the small G protein Rac1, a MAPK kinase kinase and the MAPK kinases 
(MEK) 3 and 6 (Platanias, 2003). However, whether type I IFN can regulate the p38 
MAPK system in neuronal cells has not yet been investigated. As shown in Fig. 22, 
exposure of SH-SY5Y cells to IFN-β (30 ng/ml) caused a time-dependent increase of 
dual p38 MAPK phosphorylation on Thr180/Tyr182, which is associated with an 
enhanced kinase activity. The IFN stimulation became significant at 3 h and persisted 
for at least 24 h.  
                         
 
 
Fig. 22 
 
IFN-β induces a long-lasting 
increase in p38 MAPK 
phosphorylation. SH-SY5Y cells 
were incubated in a medium 
containing 1 % FCS in the 
presence of either vehicle or 30 
ng/ml IFN-β1b  for the indicated 
periods of time. Values are the 
mean ± SEM of three experiments.  
* p < 0.05, *** p < 0.001 vs the 
respective control 
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To investigate whether IFN regulation of p38 MAPK involved JAK activity, cell were 
pre-treated with the pan-JAK inhibitor P6. Exposure to 2 µM P6 for 6 h significantly 
reduced the induction of  p38 MAPK phosphorylation induced by IFN-β (Fig. 23). 
 
                                                            Fig. 23 
 
 
 
These data indicated that in SH-SY5Y cells type I IFN could regulate p38 MAPK 
activity in a JAK-dependent manner. To gain more information on the role of this 
protein kinase in IFN action, the effects of a specific p38 MAPK inhibitor SB 203580 
on IFN-induced apoptosis of SH-SY5Y cells were examined. As shown in Figs. 24-
26, cell treatment with 10 µM SB 203580 caused a significant inhibition of IFN-β-
induced caspase-7 cleavage, PARP proteolysis and DNA fragmentation.  
 
 
 
 
 
The pan-Janus kinase (JAK) inhibitor pyridone 6 (P6) attenuates IFN-β-induced p38 MAPK 
phosphorylation. SH-SY5Y cells were treated with either vehicle or 2 μM P6 for 6 h and then 
exposed for 24 h to either vehicle or  30 ng/ml IFN-β. * p < 0.05 vs control. 
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                                                                Fig. 24 
 
                                                                       
 
           
                                                                  
 
 
 
 
 
 
    
The p38 MAPK inhibitor SB203580 attenuates IFN-β-induced caspase-7 activation. SH-SY5Y 
cells were treated with either vehicle or 10 μM SB203580 for 1 h and then exposed to either 
vehicle or IFN-β (30 ng/ml) for 24 h. Values are the mean ± SEM of three experiments. * p < 0.05 
vs IFN-β alone.   
 
Fig. 25 
 
SB203580 attenuates IFN-β-induced poly-(ADP ribose) polymerase (PARP) cleavage. SH-
SY5Y cells were treated with either vehicle or 10 μM SB203580 for 1 h and then exposed to 
either vehicle or IFN-β (30 ng/ml) for 24 h. Values are the mean ± SEM of three 
experiments. * p < 0.05 vs IFN-β alone. 
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Fig. 26 
 
Inhibition of p38 MAPK reduces IFN-β-induced DNA fragmentation. SH-SY5Y cells grown 
on glass coverslips were incubated with either vehicle or 10 μM SB203580 for 1 h and then 
treated with either vehicle or 30 ng/ml IFN-β for 24 h. The percentage of apoptotic cell nuclei 
was determined by in situ terminal transferase dUTP nick end-labeling (TUNEL) assay. 
Values are the mean ± SEM of three experiments. *** p < 0.001 vs control, # p < 0.001 vs 
IFN-β alone 
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2.3.9 Long-term treatment with IFN-β induces down-regulation of PI3K/Akt 
pathway 
In addition to the conventional JAK-STAT signaling, short-term treatment with type I 
IFNs has been found to activate the PI3K/Akt pathway, an event associated with pro-
survival effects in different cell types (van Boxel-Dezaire et al., 2006). In agreement 
with these studies, exposure of SH-SY5Y cells to IFN-β for 10 min caused a 
significant increase in Thr308 and Ser473 phosphorylation of Akt, a main 
downstream effector of PI3K, indicating an enhanced PI3K activity (Fig. 27a). 
However, 24 h treatment with IFN-β produced a decrease of Akt phosphorylation 
(Fig. 27a), which was associated with decreased Akt activity, as indicated by the 
reduced phosphorylation of exogenously added GSK-3α/β fusion protein substrate 
(Fig. 27b). Moreover, long-term treatment with IFN-β inhibited the Ser9 
phosphorylation of endogenously expressed GSK-3β (Fig. 27c). Similarly, treatment 
of primary neurons with IFN-β for 24 h caused a significant  decrease in the levels of 
phospho-(Thr308)-Akt and phospho-(Ser9)-GSK-3β (Fig. 28). 
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Fig. 27 
 
Long-term IFN-β exposure down-regulates PI3K/Akt signaling in SH-SY5Y cells. (a) 
Opposite effect on Akt phosphorylation following short-term (10 min) and long-term (24 h) 
exposure to IFN-β (30 ng/ml). Phospho-Thr308-Akt (pT308-Akt), phospho-Ser473-Akt 
(pS473-Akt) and total Akt were analyzed by Western blot and ROD values were expressed 
as percentage of the respective control. Data are the mean ± SEM of three experiments; * p 
< 0.05 vs the corresponding control value. (b) Down-regulation of Akt activity following long-
term IFN-β exposure. Akt was immunoprecipitated from cell extracts of vehicle (control) and 
IFN-β-treated (30 ng/ml for 24 h) samples and the kinase activity was assayed by 
measuring the phosphorylation of the substrate GSK-3α/β fusion protein (pGSK-3α/β f.p.) 
by Western blot. The optical density of each band was normalized to the corresponding 
density of immunoprecipitated Akt. Data are the mean ± SEM of four experiments. * p < 
0.05 vs control. (c) Reduced endogenous GSK-3β (pGSK-3β) Ser9 phosphorylation by IFN-
β treatment. Cells were incubated for 24 h with either vehicle (control) or IFN-β1b (30 ng/ml) 
and pGSK-3β and total GSK-3β were measured by Western blot. Data are the mean ± SEM 
of three experiments. * p < 0.05 vs control. 
Modified from: Dedoni et al., 2010 
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SH-SY5Y cell exposure to IGF-1 (10 ng/ml), which activates receptors coupled to 
PI3K, caused an acute increase of phospho-(Thr308)-Akt and phospho-(Ser9)-GSK-
3β levels, which was significantly attenuated in cells pre-treated with IFN-β for 24 h 
(Fig. 29). As tyrosine phosphorylation of the adaptor protein IRS-1 is involved in both 
type I IFN and  IGF-1 signaling to PI3K (Myers et al., 1993), it was important to 
examine whether the long-term exposure to IFN-β affected IRS-1 phosphorylation. 
Immunoprecipitation experiments indicated that prolonged treatment with IFN-β 
significantly reduced the basal level of phospho-Tyr-IRS-1 and the stimulation 
induced by IGF-1 (Fig. 30). To investigate the relevance of down-regulation of PI3K-
Akt signaling in IFN-β-induced apoptosis, SH-SY5Y cells were transiently transfected 
with myr-Akt1, a constitutively active construct of Akt (Kohn et al., 1996) and 
analyzed with in situ TUNEL assay. As shown in (Fig. 31), IFN-β treatment increased 
the percent of apoptotic cells in vector-transfected samples and this response was 
significantly reduced in cells expressing the constitutively active form of Akt1. 
 
Fig. 28 
 
Reduction of Akt and GSK-3β phosphorylation by long-term exposure of mouse primary cortical 
neurons to IFN-β. Cell cultures were treated for 24 h with either vehicle (control) or mouse IFN-
β (30 ng/ml) and phospho-(Thr308)-Akt, phospho-(Ser9)-GSK-3β and the corresponding total 
forms were measured by Western blot. ROD values are expressed as percent of control and 
are the mean ± SEM of three experiments. * p < 0.05 vs control. 
Modified from: Dedoni et al., 2010 
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Fig. 29 
 
Inhibition of IGF-1-induced PI3K/Akt signaling by long-term IFN-β treatment. Cells were 
incubated for 24 h with either vehicle (control) or IFN-β1b (30 ng/ml) and then exposed for 10 
min to either vehicle or IGF-1 (10 ng/ml). Phospho-Akt (pAkt), pGSK-3β, Akt and GSK-3β were 
measured by Western blot and ROD values expressed as percentage of control (vehicle + 
vehicle). Data are the mean ± SEM of three experiments. *** p < 0.001 vs control. 
Modified from: Dedoni et al., 2010 
 
 
Fig. 30 
 
Long-term IFN-β treatment attenuates IRS-1 tyrosine phosphorylation. Cells were incubated for 
24 h with either vehicle (control) or IFN-β1b (30 ng/ml) and then exposed for 10 min to either 
vehicle or IGF-1 (10 ng/ml). IRS-1 was immunoprecipitated from cell extracts and the level of 
IRS-1 tyrosine phosphorylation was determined by Western blot. The optical density of each 
band was normalized to the corresponding density of immunoprecipitated IRS-1 (i.p. IRS-1). 
Data are the mean ± SEM of three experiments.  *** p < 0.001 vs control. 
Modified from: Dedoni et al., 2010 
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2.3.10 GSK-3 inhibition prevents PKR induction and apoptosis by IFN-β 
Recent studies have demonstrated that GSK-3β is not only involved in glucose 
metabolism but also regulates the apoptosis cascade in several cell types (Beurel et 
al, 2006). This kinase is constitutively active and its activity is inhibited by 
phosphorylation on Ser9. The finding that long-term exposure to IFN caused an 
evident decrease in GSK-3β phosphorylation on Ser9, indicated an up-regulation of 
GSK-3β activity. This observation raised the question as to whether this protein 
kinase was an essential component of the IFN-triggered programmed cell death. 
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Fig. 31 
 
Constitutively active Akt1 attenuates IFN-β-induced apoptosis. Cells were transfected with 
either empty vector or a constitutively active construct of Akt1 (myr-Akt1) and then treated with 
vehicle or IFN-β1b (30 ng/ml) for 24 h. The percentage of apoptotic cell nuclei was determined 
by in situ TUNEL assay. Data are the mean ± SEM of three experiments. *** p < 0.001 vs 
empty vector + vehicle. Scale bar = 100 µm.  
Modified from: Dedoni et al., 2010 
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To address this issue, the compounds SB216763 and AR A014418, two  structurally 
different inhibitors of GSK-3α and GSK-3β, were used. Pre-treatment of SH-SY5Y 
cells with SB216763 almost completely prevented caspase-9, - 7 and -3 activation 
caused by 24 h exposure to IFN-β (Fig. 32).  
             
         
      
 
Similarly, cell treatment with AR A014418 attenuated IFN-β-induced increase of PKR 
expression and activation of caspase-7 (Fig. 33).  
    
 
Fig. 32 
 
The GSK-3 inhibitor SB216763 
prevent caspases activation by 
IFN-β.Cells were preincubated 
for 1 h with either vehicle 
(control) or 5 µM SB 216763 
and then treated with either 
vehicle or IFN-β1b (30 ng/ml) 
for 24 h. Cell extracts were 
prepared and analyzed for 
caspase cleavage  by Western 
blot. Values are the mean ± 
SEM of three experiments. 
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In addition, analysis of cell DNA fragmentation  by the TUNEL assay indicated that 
cell pre-treatment with SB216763 significantly reduced the percentage of cells 
undergoing apoptosis following treatment for 24 h with IFN-β (Fig.  34).  
Fig 33 
 
The GSK-3 inhibitor AR A014418 prevents PKR induction and caspase-7 activation by IFN-
β. Cells were preincubated for 1 h with either vehicle (control) or 10 µM AR 0A14418 and 
then treated with either vehicle or IFN-β1b (30 ng/ml) for 24 h. Cell extracts were prepared 
and analyzed for PKR expression  and caspase-7 cleavage by Western blot. Values are 
the mean ± SEM of three experiments. 
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Fig. 34 
 
The GSK-3 inhibitor SB 216763 reduces IFN-induced DNA fragmentation. Cells were 
preincubated for 1 h with either vehicle (control) or 5 µM SB 216763 and then treated with 
either vehicle or 30 ng/ml IFN-β1b for 24 h. Cells were then washed, fixed and incubated with 
fluorescein-12-dUTP and recombinant Terminal Deoxynucleotidyl Transferase. Cell nuclei 
were stained with DAPI. Cells were analyzed by fluorescence microscopy. The cell nuclei 
showing a green fluorescence were counted and their number was reported as percent of 
total nuclei. Values are the mean ± SEM of three determinations.  
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2.3.11 Long-term type I IFN treatment inhibits BDNF receptor signaling and 
neuritogenesis. 
A number of studies have linked a dysregulation of  brain-derived neurotrophic factor 
(BDNF) receptor signaling to the pathogenesis of different neurodegenerative 
diseases and neuropsychiatric disorders (Hashimoto et al., 2004; Hu and Russek, 
2008). It has been reported that BDNF action could be impaired in depression, 
stress-related affective disorders and schizophrenia. In postmortem brain samples of 
depressed and schizophrenic patients BDNF levels have been found to be reduced 
(Weickert et al., 2003; Hashimoto et al., 2005).  Moreover, in humans chronic 
administration of several antidepressants, including selective serotonin reuptake 
inhibitors, increases and restores BDNF expression (Nibuya et al., 1995; Chen et al., 
2001; Castrèn et al., 2004; Kozisek et al., 2008).  
BDNF exerts its biological actions through the stimulation of a specific cell-surface 
receptor, which belongs to the family of the tyrosine kinase-coupled receptors, known 
as  tropomyosin receptor kinase B (TrkB). 
Previous studies have shown that SH-SY5Y cells differentiated with RA express  
TrkB receptors and are responsive to the neurotrophic effects of BDNF (Kaplan et al., 
1993; Encinas et al., 1999; Xie et al., 2010).  Therefore, it was of interest to 
investigate whether long-term exposure of differentiated SH-SH5Y to type I IFNs 
could affect BDNF-induced responses, such as TrkB signaling and neuronal 
differentiation.   
As shown in Fig. 35, short-term exposure of RA-differentiated SH-SY5Y cells to 
BDNF (0.9 nM) elicited a marked increase of Akt phosphorylation at Thr308, which 
was associated with an increase in the inhibitory phosphorylation of GSK-3β at Ser9. 
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Both BDNF responses were significantly reduced by cell preincubation for 24 h with 
30 ng/ml IFN-β (Fig. 35). 
                         
                      
 
 
 
 
 
Besides regulating the PI3K/Akt/GSK-3β pathway, BDNF has been reported to 
promote the phosphorylation of the ERK1/2 MAPK in SH-SY5Y cells (Encinas et al., 
1999). Cell exposure to IFN-β for 24 h was found to significantly decrease the 
stimulation of ERK1/2 elicited by acute treatment with BDNF (Fig. 36). 
Previous studies have shown that, as compared to RA and PMA alone, differentiation 
of  SH-SY5Y cells with sequential RA and PMA treatment exhibited the highest level 
Fig. 35 
 
IFN-β inhibits BDNF-stimulated Akt and GSK-3β phosphorylation in differentiated SH-SY5Y 
cells. SY-SY5Y cells were differentiated by exposure to 10 μM retinoic acid for 6 days. Cells 
were treated with either vehicle or IFN-β (30 ng/ml) for 24 h and then exposed  to either vehicle 
or 0.9 nM human BDNF for 5 min. Cell lysates were then assayed for phospho-(Thr308)-Akt 
and phospho-(Ser9)-GSK-3β. Values are the mean ± SEM of three experiments. * p < 0.05, *** 
p < 0.001 vs control. # p < 0.05 vs BDNF alone. 
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of tyrosine hydroxylase (TH), the rate-limiting  enzyme in catecholamine synthesis 
(Presgraves et al., 2004). In RA/PMA differentiated SH-SY5Y cells, BDNF (0.9 nM) 
caused an increase in the level of TH phosphorylation at Ser31 and this effect was 
curtailed by cell pre-treatment with IFN-β (Fig 37). 
 
                           
 
 
 
 
                                               
                         
    
 
 
Fig. 36 
 
IFN-β attenuates BDNF-induced stimulation of  ERK1/2  phosphorylation in differentiated SH-
SY5Y cells.  RA-differentiated SH-SY5Y cells were treated with either vehicle or IFN-β (30 
ng/ml) for 24 h and then exposed  to either vehicle or 0.9 nM human BDNF for 5 min. Cell 
lysates were then assayed for phospho-ERK1/2. Values are the mean ± SEM of three 
experiments. * p < 0.05, *** p < 0.001 vs control. # p < 0.05 vs BDNF alone. 
 
Fig. 37 
 
SH-SY5Y were differentiated by sequential treatment with RA for two days and  PMA for two 
additional days. Cells were incubated for 24 h with either vehicle or IFN-β (30 ng/ml) and then 
exposed to either vehicle or 0.9 nM BDNF for 5 min. Values are the mean ± SEM of three 
experiments.*** p < 0.001 vs control, # p < 0.001 vs BDNF alone.  
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In RA-differentiated SH-SY5Y cells, prolonged treatment with BDNF has been 
reported to induce a significant increase in the number of cells exhibiting neuritic 
processes (Encinas et al., 1999). To investigate whether exposure to type I IFNs 
could affect BDNF-stimulated neuritogenesis, SH-SY5Y cells were differentiated with 
RA and then incubated for 48 h with 2 nM BDNF alone or in association with IFN-β 
(30 ng/ml). Cells were then stained with FITC-conjugated phalloidin and NF160/200.  
In line with previous observations (Encinas et al., 1999), it was found that, as 
compared to control cells, BDNF-treated cells exhibited a higher number of neurites, 
which were also longer and branched (Fig. 38). Moreover, BDNF-treated cells 
displayed smaller cell bodies with an oval shape and appeared to spread over the 
dish surface. The co-addition of IFN-β counteracted  these morphological changes, 
causing the cells to become flattened  with fewer and shorter processes (Fig. 38). 
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Fig. 38 
 
IFN-β inhibits BDNF-induced neuritogenesis in SH-SY5Y cells. RA-differentiated SH-SY5Y cells 
were incubated with either vehicle, 2 nM BDNF, 30 ng/ml IFN-β or the combination of IFN-β and 
BDNF for 48 h. Cells were then stained with anti-neurofilament 160/200 (red), FITC-conjugated 
phalloidin (green) and DAPI (blue). Data are representative of  three similar experiments.  
** p < 0.01 vs vehicle. # p< 0.01 vs BDNF alone. 
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3. Discussion 
Previous studies examining the mechanisms of type I IFN neurotoxicity have mainly 
postulated indirect effects of the cytokines mediated by an action on either peripheral 
organs or glial cells. In the present study  we show that type I IFNs can act on 
neuronal cells to promote apoptotic death, thus indicating that neurons may 
constitute a direct cellular target of the neurotoxic action of these cytokines.  The pro-
apoptotic effects of type I IFNs were observed in primary cultures of mouse cortical 
neurons and in SH-SY5Y neuroblastoma cells. Conversely, under similar 
experimental conditions, IFN-β failed to cause cell death in the HeLa cell line, which 
also expresses functional IFNAR. This observation suggests that neuronal cells are 
particularly sensitive to the cytotoxic effects of type I IFNs. 
The pro-apoptotic action of IFNs appeared to be dependent on the regulation of 
different signaling pathways, which are known to govern cell survival through 
transcriptional, translational and post-translational mechanisms.  
 
3.1 Role of JAK-STAT signaling in IFN-induced apoptosis. 
In neuronal cells, type I IFNs behaved as effective stimulators of JAK-STAT 
signaling. In SH-SY5Y cells IFN-α and -β elicited a rapid induction of Tyk2, STAT1, 
STAT3 and STAT5 tyrosine phosphorylation at concentrations in the picomolar 
range, indicating that the cells possess a  type I IFN receptor with high affinity for the 
cytokines. A robust increase of STAT1 and STAT3 phosphorylation by IFN-β was 
similarly observed in mouse primary neurons. In SH-SY5Y cells the expression of a 
specific type I IFN receptor was further supported by the ability of an anti-IFNAR2 
neutralizing antibody to completely block STAT1 phosphorylation induced by IFN-β. 
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Impairment of JAK activity by the potent pan-JAK inhibitor P6 attenuated Tyk2, 
STAT1 and STAT3 tyrosine-phosphorylation and ISRE transcriptional activity. 
Moreover, P6 treatment prevented IFN-β-induced caspase activation in both SH-
SY5Y cells and mouse primary neurons. Among the STAT family members, STAT1 
has been shown to promote anti-proliferative effects and different forms of cell death 
in response to cytokines through transcription-dependent and –independent 
processes (Kim and Lee, 2007). On the other hand, in various cell types STAT3 and 
STAT5 have generally been reported to induce the expression of anti-apoptotic and 
pro-survival genes (Schindler et al., 2007) and in THP-1 human monocytic cells 
STAT3 has been found to antagonize STAT1 dependent transcription in response to 
type I IFNs (Ho and Ivashkiv, 2006). Although in SH-SY5Y cells type I IFNs acutely 
stimulated tyrosine-phosphorylation of STAT1, STAT3 and STAT5, prolonged 
treatment with IFN-β caused a more robust induction and a more persistent 
phosphorylation of STAT1 than STAT3 or STAT5. Thus, the induction of apoptosis in 
SH-SY5Y cells appeared to be associated with an imbalance between STAT1, 
STAT3 and STAT5 activation states. 
 
3.2 Involvement of PKR 
PKR is one of the most characterized death-modulating protein induced by type I 
IFNs through the activation of STAT1. PKR activated by dsRNAs generated during 
viral infections, or by direct interaction with the activator protein PACT/RAX, 
undergoes dimerization and autophosphorylation. Activated PKR then 
phosphorylates eIF-2α, thereby inhibiting mRNA translation, cell growth or viral 
replication (Gil and Esteban, 2000). In SH-SY5Y cells, IFN-β caused a time-
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dependent increase in the level of PKR protein expression, which was dependent on 
RNA synthesis and JAK-STAT signaling, as indicated by the sensitivity to P6 and 
STAT1 siRNA treatments. The enhanced PKR levels were associated with enhanced 
activity leading to an increased phosphorylation of eIF-2α. Inhibition of PKR 
prevented IFN-β-induced activation of the caspase proteolytic cascade, indicating 
that PKR played a major role in the IFN-β-triggered apoptotic process. Previous 
studies on PKR-induced apoptosis have clearly established that eIF-2α 
phosphorylation is an essential step, but the precise connection between PKR 
activity and cell death is still unknown. Two main pathways linking PKR to cell death 
have been hypothesized: one mediated by activation of the transcription factor NF-κB 
leading to increased expression of pro-apoptotic proteins, such as  Fas, Bax and 
p53, and the other involving caspase-8 activation through the death receptor FADD 
(Gil and Esteban, 2000). Whether these mechanisms contribute to IFN-β-induced 
apoptosis in SH-SY5Y cells remains to be investigated. However, in agreement with 
other studies (Hopkins-Donaldson et al., 2000) pro-caspase-8 and its proteolytic 
fragments were not detected in SH-SY5Y cells under basal conditions and following 
treatment with IFN-β or TNF-α, thus making the involvement of this caspase pathway 
unlikely.  
An additional mechanism of PKR-induced apoptosis may involve the transcriptional 
activation of the gene for C/EBP (CCAAT/enhancer binding protein) homologous 
protein (CHOP), also known as growth arrest and DNA damage inducible gene 153 
(GADD153), which is a component of the endoplasmic reticulum stress (Oyadomari 
and Mori, 2004). Although phosphorylation of eIF-2α causes a general attenuation of 
translation, this condition allows the efficient  translation of the activating transcription 
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factor (ATF) 4 mRNA, since this mRNA contains small upstream open-reading 
frames (uORF) within the 5’-untranslated region, which allows to overcome the 
blockade induced by phosphorylated eIF-2α. Once translated, ATF4 migrates to the 
nucleus where it binds to the cis-acting elements AARE 1 and AARE2, which are 
known to regulate the transcription of CHOP. CHOP is a pro-apoptotic 29 kDa protein 
composed of two known functional domains, a N-terminal transcriptional activation 
domain and a C-terminal basic-leucine zipper (bZIP) domain formed by a basic 
amino acid rich DNA-binding region followed by a leucine zipper dimerization motif. 
The bZip domain allows the formation of heterodimers with other C/EBP family 
member of transcription factors that prefer to form homodimers, As a consequence, 
CHOP-C/EBP heterodimers cannot bind to C/EBP sites and regulate a variety of 
genes involved in cell differentiation and proliferation. Moreover, overexpression of 
CHOP leads to a decrease of the anti-apoptotic protein Bcl-2 (McCullough et al., 
2001) and to translocation of the pro-apoptotic protein Bax from the cytosol to the 
mitochondria (Gotoh et al., 2004). Thus, CHOP induction triggered by enhanced  eIF-
2α phosphorylation by PKR may contribute to IFN-induced neuronal death by 
enhancing the mitochondrial apoptotic pathway (Fig. 39).   
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3.3 Role of p38 MAPK in IFN-induced neuronal apoptosis 
Although considered as an ancillary pathway of IFN signaling, the p38 MAPK has 
been reported to play a critical role in IFN cellular actions. In different cell types, 
treatment with the p38 MAPK inhibitor SB203580 or overexpression of a dominant-
negative p38 MAPK mutant inhibited IFN-α-dependent gene transcription via ISRE 
and GAS elements (Uddin et al., 1999, 2000; Goh et al., 1999). Moreover, p38 MAPK 
activity has been shown to be required for IFN-induced antiviral activity (Goh et al., 
1999), growth inhibitory effects on human hematopoiesis  (Verma et al., 2002) and 
antiproliferative effects in leukaemia cells (Mayer et al., 2001).  
The present study shows that in SH-SY5Y cells IFN-β induced a significant increase 
of the  phosphorylation of p38 MAPK, indicating that the cytokine can regulate this 
MAPK pathway also in neuron-like cells. The enhanced p38 MAPK phosphorylation 
became significant after a lag time of about 3 h, suggesting that the coupling of IFN-
activated IFNAR to p38 MAPK stimulation was slow and possibly required a multistep 
Fig. 39 
 
Possibile involvement of the pro-
apoptotic CHOP  in PKR-induced 
neuronal death.  
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process. Cell treatment with P6 prevented IFN-β-induced p38 MAPK 
phosphorylation, a finding in line with previous studies reporting that JAK activity is 
required to trigger the signaling cascade leading to p38 MAPK activation (Platanias, 
2003). Cell treatment with SB203580 prevented IFN-β-induced caspase activation 
and DNA fragmentation, indicating that p38 MAPK activity was involved in the 
apoptotic process. The mechanism(s) by which p38 MAPK may promote apoptosis in 
IFN-treated SH-SY5Y cells have not been investigated. As mentioned above, p38 
MAPK  has been found to facilitate IFN-dependent gene transcription and, therefore, 
may potentiate STAT-dependent mechanisms of apoptosis. However, in the present 
study blockade of p38 MAPK  with SB203580 failed  to prevent PKR induction by 
IFN-β (results not shown), suggesting that in SH-SY5Y cells p38 MAPK did not cause 
apoptosis through enhanced expression of PKR. In other cell types it has been 
reported that p38 MAPK  can promote apoptosis through different mechanisms, 
including retinoblastoma protein phosphorylation (Yeste-Velasco et al., 2009), Bax 
translocation to mitochondria (Capano and Crompton, 2006) and CHOP 
phosphorylation (Wang and Ron, 1996). 
In the brain activation of p38 MAPK has been associated with neuroinflammation 
(Munoz and Ammit, 2010) and  has been proposed to mediate κ-opioid dependent 
dysphoria (Bruchas et al., 2007)  and stress-induced depression (Duric et al., 2010). 
In the rat embryonic raphe cell line RN46A and mouse midbrain and striatal 
synaptosomes p38 MAPK has been shown to mediate the stimulation of the 
serotonin transporter  induced by IL6 and TNF-α (Zhu et al., 2006), thus establishing 
a possible pathogenetic link between cytokines, p38 MAPK and depression (Miller 
and Raison, 2006). 
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3.4 Down-regulation of PI3K/Akt pathway 
A large body of genetic and pharmacological evidence indicates that the PI3K/Akt 
signaling pathway is critical for cell growth and survival (Hennessy et al., 2005). 
Previous studies have shown that short-term exposure to type I IFNs can activate 
PI3K through multiple mechanisms, including phosphorylation of STAT3, which 
functions as docking site for PI3K p85 regulatory subunit, IRS-1 tyrosine 
phosphorylation, and constitutive association of PI3K with IFNAR1 subunit of IFN 
receptor (van Boxel-Dezaire et al., 2006). By stimulating PI3K/Akt signaling, type I 
IFNs have been found to promote the survival of primary astrocytes (Barca et al., 
2003), neutrophils (Wang et al., 2003) and B lymphocytes (Ruuth et al., 2001). Akt 
inactivates several pro-apoptotic factors, including the BAD protein, procaspase-9 
and Forkhead transcription factors, and activates IkB kinase, leading to nuclear 
localization of the anti-apoptotic transcription factor NF-kB (Hennessy et al., 2005). 
Akt phosphorylates GSK-3β on Ser9 and  inhibits GSK-3β, a key enzyme in 
promoting the intrinsic apoptotic pathway (Pap and Cooper, 1998). In addition, acute 
PI3K activation has been proposed to promote mRNA translation of IFN-stimulated 
genes via activation of mammalian target of rapamycin (mTOR) (Kaur et al., 2008). In 
SH-SY5Y cells we observed that a brief exposure to IFN-β increased Akt 
phosphorylation, whereas a prolonged incubation with the cytokine led to down-
regulation of Akt signaling, as indicated by the decreased phosphorylation and 
activation of Akt and reduced GSK-3β phosphorylation. Long-term treatment with 
IFN-β also inhibited Akt and GSK-3β phosphorylation in mouse primary neurons. The 
down-regulation of Akt signaling was likely due to a decreased activation of PI3K, as 
in SH-SY5Y cells IFN-β exposure led to a reduced responsivity to IGF-1, which 
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stimulates Akt by activating receptors coupled to PI3K. Cell transfection with 
constitutively active Akt reduced IFN-β-induced apoptosis, indicating that IFN-
inhibited Akt signaling affected neuronal survival. Thus, it is possible that the down-
regulation of PI3K/Akt activity may promote neuronal death by facilitating the 
activation of the intrinsic apoptotic pathway.  
The precise molecular mechanisms mediating the IFN-β-induced down-regulation of 
PI3K/Akt signaling remain unknown. In SH-SY5Y cells we have found that prolonged 
IFN-β treatment led to a reduced tyrosine phosphorylation of IRS-1, which is a critical 
component of PI3K recruitment and activation process by both IFN and growth factor 
receptors (Uddin et al., 1995). This change could therefore have been involved in 
down-regulation of PI3K/Akt signaling. The altered tyrosine phosphorylation state of 
IRS-1 could have been a consequence of a decreased JAK activity (Burfoot et al., 
1997), possibly due to the action of suppressor of cytokine signaling family of 
proteins, which are known to be induced by IFNs and to provide a negative feedback 
loop on IFN signaling by direct JAK inhibition (Shuai and Liu, 2003). However, since 
IFN treatment also led to a decreased IRS-1 phosphorylation in response to IGF-1, 
additional mechanisms including protein tyrosine phosphatases (PTPs) could have 
been involved. Several PTPs known to promote IRS-1 dephosphorylation, such as 
PTP1B and SHP-2 (Goldstein et al., 2000), also participate in the regulation of 
strength and duration of IFN signaling (Shuai and Liu, 2003). Interestingly, it has 
recently been reported that IRS-1 is dephosphorylated by the protein tyrosine 
phosphatase PTPL1, which causes apoptosis and inhibits PI3K/Akt pathway 
(Dromard et al., 2007). Further studies are required to investigate whether this or 
other PTPs is involved in IFN-induced neuronal cell death. 
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3.5 Role of GSK-3 in IFN-induced neuronal damage. 
As mentioned above, along the PI3K/Akt pathway GSK-3 works as a major regulator 
of cell survival and an impaired inhibition of GSK-3β via phosphorylation at Ser9  has 
been associated with mood disturbances, schizophrenia and neurodegenerative 
disorders (Beurel and Jope, 2006; Prickaerts et al., 2006; Rowe et al., 2007; Hooper 
et al., 2008; Li and Jope, 2010). Increasing evidence also indicates that GSK-3 is a 
key regulator of neurodevelopmental processes, including neurogenesis, neuronal 
migration, neuronal polarization and axon growth and guidance (Hur and Zhu, 2010). 
Moreover, inhibition of GSK-3 signaling is required for hippocampal long-term 
potentiation, a synaptic model of learning and memory (Hooper et al., 2007). 
In either primary cultures of mouse cortical neurons and SH-SY5Y cells long-term 
exposure to type I IFNs led to a reduced phosphorylation of GSK-3β at Ser9, 
indicating an enhanced kinase activity. Moreover, the results obtained with the two 
inhibitors SB216763 and AR A014418 highlight a crucial role of GSK-3 in neuronal 
death caused by IFN exposure. In fact, blockade of activity prevented the IFN-
induced activation of caspase cascade and significantly reduced IFN-stimulated DNA 
fragmentation, indicating a close involvement in the apoptotic outcome.  
GSK-3β has previously been found to promote amyloid-β-induced neurotoxicity 
(Takashima et al., 1993), and its overexpression in the rat pheocromocytoma cell line 
PC12 caused apoptosis (Pap and Cooper, 1998). In addition, GSK-3β has also been 
involved in neuronal apoptosis induced by trophic withdrawal (Hetman et al., 2000; 
Mishra et al., 2007; Wang et al., 2009), the human immunodeficiency virus type 1 
regulatory protein Tat (Maggirwar et al., 1999) and 6-hydroxydopamine (Li et al., 
2011).   
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Different mechanisms may mediate the pro-apoptotic effects of GSK-3β. This protein 
kinase has been reported to regulate cell activity and survival by controlling both 
transcriptional and non-trascriptional events. GSK-3β phosphorylates and affects the 
function or stability of various transcription factors that control genes governing cell 
fate and differentiation, such as p53, β-catenin, heat-shock factor 1 (HSF-1), myc, 
NF-κB and cyclic AMP responsive element binding (CREB) protein (Beurel and Jope, 
2006). With regard to neuronal apoptosis, both inhibition of HSF-1 and  CREB has 
been proposed to play a role. Once activated, HSF-1 induces the expression of heat 
shock proteins that detect and chaperone denaturated and misfolded proteins. 
Similarly, inhibition of CREB transcriptional activity may participate in the pro-
apoptotic effect of GSK-3β, as CREB has a critical role in promoting neuronal 
survival (Walton and Dragunow, 2000). Moreover, CREB is involved in many central 
functions negatively affected by IFN administration, such as mood regulation 
(Pandey, 2004) and cognitive processes (Silva et al., 1998; Benito and Barco, 2010). 
More recently, GSK-3β has been reported to cause neuronal apoptosis through 
phosphorylation and inactivation of the transcription factor myocyte  enhancer factor 
2D (MEF2D), which promotes neuronal survival (Wang et al., 2009). 
GSK-3 can also induce apoptosis through non-transcriptional mechanisms, including 
phosphorylation of the microtubule-associated protein tau and consequent 
microtubule destabilization (Johnson and Bailey, 2002), the pro-apoptotic protein Bax 
(Linseman et al., 2004) and the mitochondrial voltage-dependent anion channel 
(VDAC) involved in the control of mitochondrial membrane potential. The  GSK-3-
induced phosphorylation of VDAC prevents its association with hexokinase II and 
favours the binding of pro-apoptotic Bcl-2 family proteins with a consequent 
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enhancement of mitochondrial permeability (Pastorino et al., 2005). Moreover, GSK-
3β has been proposed to induce neuronal apoptosis through phosphorylation and 
activation of the mixed lineage kinase 3 (MLK3), which triggers the JNK pathway 
(Mishra et al., 2007).  
Inhibition of GSK-3 with AR A014418 was found to prevent the increased expression 
of PKR caused by long-term IFN-β treatment, suggesting that GSK-3 regulates IFN 
transcriptional activity. A recent study has shown that in mouse primary astrocytes, 
microglia and macrophage-derived RAW264.7 cells, IFN-γ/LPS-induced STAT3 
tyrosine phosphorylation was greatly reduced by GSK-3 inhibitors and that GSK-3β 
bound to STAT3 and associated with IFN-γ receptor (Beurel and Jope, 2008). Thus, 
it is possible that the protective effects of GSK-3 inhibitors against IFN-β-induced 
apoptosis may also result from a reduced STAT activation. It remains to be 
investigated whether in SH-SY5Y cells  GSK-3 regulates STAT1 phosphorylation 
through a direct interaction with IFNAR.  
Interestingly, antidepressant drugs have been reported to inhibit GSK-3β by 
increasing Ser9 phosphorylation (Beurel and Jope, 2006; Prickaerts et al., 2006; 
Rowe et al., 2007). Antidepressants are also effective in preventing type I IFN-
induced depression (Raison et al., 2005). It is therefore possible that inhibition of  
IFN-enhanced GSK-3β activity may contribute to the beneficial effects of these drugs 
against  the mood disturbances associated with IFN therapy. This hypothesis 
requires experimental validation. 
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3.6 IFN-induced inhibition of BDNF signaling and neurotrophic effects. 
The long-term exposure of RA-differentiated SH-SY5Y cells to type I IFNs was found 
to markedly affect the ability of BDNF to regulate intracellular signaling and neuronal 
differentiation. The activation of Akt and the increased phosphorylation of GSK-3β at 
Ser9, two events associated with BDNF-stimulated neuronal survival and 
antidepressant effects (Encinas et al., 1999; Mai et al., 2002) were significantly 
reduced in cell pre-exposed to IFN-β. The inhibitory effects of IFN-β were not limited 
to BDNF-activated PI3K/Akt signaling but also involved  BDNF stimulation of ERK1/2 
MAPK pathway, suggesting a wide suppressant effect on Trk signaling. In SH-SY5Y 
cells, ERK1/2 activation has been found to be necessary for BDNF-induced 
neuritogenesis (Encinas et al., 1999). It was found that IFN-β significantly reduced 
BDNF-stimulated neurite outgrowth, indicating that the inhibition of  ERK1/2 
activation had relevant consequences on neuronal differentiation induced by the 
neurotrophin. 
Another important outcome of ERK1/2 inhibition may be represented by the reduction 
of BDNF-stimulated TH phosphorylation at Ser31 in cell pre-exposed to IFN-β. 
Activation of the ERK1/2 pathway has been reported to induce TH phosphorylation at 
Ser31 and to stimulate catecholamine synthesis (Haycock et al., 1992; Halloran and 
Vulliet, 1994; Bobrovskaya et al., 2001; Lindgren et al., 2002). As impaired nor-
adrenergic transmission may be associated with depression (Delgado, 2000), the 
IFN-induced inhibition of BDNF-stimulated TH phosphorylation and the possible 
associated reduction of catecholamine synthesis may contribute to the mood 
disturbances elicited by type I IFNs. 
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A recent study has proposed that stress stimuli may impair ERK1/2 activity through 
p38 MAPK-dependent induction of the MAPK phosphatase-1 (MKP-1), a tyrosine and 
serine/threonine phosphatase that targets MAPK (Duric et al., 2010). In future 
studies, it will be important to assess whether IFN-induced inhibition of ERK1/2 
signaling is consequent to p38 MAPK activation and involves an enhanced 
expression of MKP family members. 
 
Conclusions 
In conclusion, the present study provides the first demonstration that type I IFN can 
act directly on neuronal cells to impair cell survival through multiple mechanisms, 
including stimulation of JAK-STAT signaling, PKR induction and activation, enhanced 
p38 MAPK activity, down-regulation of the PI3K/Akt pathway and attenuation of 
BDNF signaling (Fig 40). In SH-SY5Y cells, these intracellular signals may cooperate 
to promote mitochondria damage, thereby triggering cytochrome C release, 
activation of caspase cascade and apoptosis. Moreover, the antagonism of 
neurotrophin action may lead to impairment of neuritogenesis and reduced 
catecholamine neurotransmission. Neuronal apoptosis and altered synaptic plasticity 
are  considered relevant neuropathological substrates of several neurodegenerative 
and neuropsychiatric disorders (Mattson, 2000; McKernan et al, 2009). It is therefore 
possible that these functional and structural alterations of the neuronal network may 
contribute to the pathogenesis of the central neurotoxic  effects of type I IFNs. 
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Fig. 40 
 
Proposed intracellular pathways mediating neuronal damage induced by type I IFNs. The green 
and red lines arrows indicate stimulatory  and inhibitory pathways, respectively. NA., nor-
adrenaline, NTF, neurotrophic factor. 
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